{"id":"brigatinib","rwe":[{"pmid":"41898726","year":"2026","title":"Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41893038","year":"2026","title":"Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review.","finding":"","journal":"Journal of personalized medicine","studyType":"Clinical Study"},{"pmid":"41827693","year":"2026","title":"GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41810993","year":"2026","title":"Brigatinib-induced psoriasiform dermatitis successfully treated with deucravacitinib.","finding":"","journal":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","studyType":"Clinical Study"},{"pmid":"41756440","year":"2026","title":"N-Cadherin Dynamically Regulates Schwannoma Migration and Represents a Novel Therapeutic Target in NF2-Related Schwannomatosis.","finding":"","journal":"Research square","studyType":"Clinical Study"}],"_fda":{"id":"176eb255-05c0-4cfc-874f-1fb57136d34d","set_id":"0fe9ff20-d402-41f3-bc1e-7002ea7007db","openfda":{"nui":["N0000175605","N0000020001","N0000190118"],"unii":["HYW8DB273J"],"route":["ORAL"],"rxcui":["1921222","1921228","1925494","1988768","1988770","1988772","1988785","1988786"],"spl_id":["176eb255-05c0-4cfc-874f-1fb57136d34d"],"brand_name":["Alunbrig"],"spl_set_id":["0fe9ff20-d402-41f3-bc1e-7002ea7007db"],"package_ndc":["63020-113-30","63020-090-30","63020-090-07","63020-180-30","63020-198-30","63020-180-23"],"product_ndc":["63020-090","63020-113","63020-180","63020-198"],"generic_name":["BRIGATINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["BRIGATINIB"],"pharm_class_epc":["Kinase Inhibitor [EPC]"],"pharm_class_moa":["Tyrosine Kinase Inhibitors [MoA]","Cytochrome P450 3A Inducers [MoA]"],"manufacturer_name":["Takeda Pharmaceuticals America, Inc."],"application_number":["NDA208772"],"is_original_packager":[true]},"version":"17","pregnancy":["8.1 Pregnancy Risk Summary Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no clinical data on the use of ALUNBRIG in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily) as well as increased post-implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or greater (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal development study in which pregnant rats were administered daily doses of brigatinib during organogenesis, dose-related skeletal (incomplete ossification, small incisors) and visceral anomalies were observed at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily). Malformations observed at 25 mg/kg/day (approximately 1.26 times the human AUC at 180 mg once daily) included anasarca (generalized subcutaneous edema), anophthalmia (absent eyes), forelimb hyperflexion, small, short and/or bent limbs, multiple fused ribs, bent scapulae, omphalocele (intestine protruding into umbilicus), and gastroschisis (intestines protruding through a defect in the abdominal wall) along with visceral findings of moderate bilateral dilatation of the lateral ventricles."],"description":["11 DESCRIPTION Brigatinib is a kinase inhibitor. The chemical name for brigatinib is 5-chloro-N 4 -[2-(dimethylphosphoryl)phenyl]-N 2 -{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine. The molecular formula is C 29 H 39 ClN 7 O 2 P which corresponds to a formula weight of 584.10 g/mol. Brigatinib has no chiral centers. The chemical structure is shown below: Brigatinib is an off-white to beige/tan solid. The pK a s were determined to be: 1.73 ± 0.02 (base), 3.65 ± 0.01 (base), 4.72 ± 0.01 (base), and 8.04 ± 0.01 (base). ALUNBRIG is supplied for oral use as film-coated tablets containing 180 mg, 90 mg or 30 mg of brigatinib and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 180 mg tablets: oval, white to off-white film-coated tablets with \"U13\" debossed on one side and plain on the other side; available in: Bottle of 23 tablets NDC 63020-180-23 Bottle of 30 tablets NDC 63020-180-30 90 mg tablets: oval, white to off-white film-coated tablets with \"U7\" debossed on one side and plain on the other side; available in: Bottle of 7 tablets NDC 63020-090-07 Bottle of 30 tablets NDC 63020-090-30 30 mg tablets: round, white to off-white film-coated tablets with \"U3\" debossed on one side and plain on the other side; available in: Bottle of 30 tablets NDC 63020-113-30 90 mg / 7 count tablets (NDC 63020-090-07) and 180 mg / 23 count tablets (NDC 63020-180-23) are also available in a single carton as a one-month initiation pack: One carton containing one bottle of 90 mg tablets (7 count) and one bottle of 180 mg tablets (23 count) NDC 63020-198-30 Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) (see USP)."],"geriatric_use":["8.5 Geriatric Use Of the 359 patients enrolled in the ALTA 1L ALUNBRIG arm and in ALTA, 26.7% were 65 and older and 7.5% were 75 and older. No overall differences in safety or effectiveness were observed between patients ≥65 years and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of ALUNBRIG in pediatric patients have not been established."],"effective_time":"20260112","clinical_studies":["14 CLINICAL STUDIES TKI-naïve Advanced ALK-positive NSCLC (ALTA 1L Study) The efficacy of ALUNBRIG was demonstrated in a randomized (1:1), open-label, multicenter trial (ALTA 1L, NCT02737501) in adult patients with advanced ALK-positive NSCLC who had not previously received an ALK-targeted therapy. The study required patients to have an ALK rearrangement based on a local standard of care testing. Eligible patients were allowed to have up to 1 prior regimen of chemotherapy in the locally advanced or metastatic setting and were required to have an ECOG Performance Status of 0-2. Neurologically stable patients with treated or untreated central nervous system (CNS) metastases, including leptomeningeal metastases, were eligible. Patients with a history of interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis were excluded. The major efficacy outcome measure was progression-free survival (PFS) as evaluated by a Blinded Independent Review Committee (BIRC) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Additional efficacy outcome measures included confirmed overall response rate (ORR), duration of response (DOR), intracranial ORR, and intracranial DOR as evaluated by BIRC, and overall survival (OS). A total of 275 patients were randomized to receive ALUNBRIG 180 mg orally once daily with a 7-day lead-in at 90 mg once daily (n = 137) or crizotinib 250 mg orally twice daily (n = 138). Of the 275 enrolled patients, 239 had positive results using the companion diagnostic test, the Vysis ALK Break Apart FISH Probe Kit; central results were negative for 20 patients and unavailable for 16 patients. Crossover from the crizotinib arm to the ALUNBRIG arm was permitted following disease progression. Randomization was stratified by CNS metastases (present vs absent) and prior chemotherapy use for locally advanced or metastatic disease (yes, no). Baseline demographic characteristics of the overall study population were: median age 59 years (range: 27 to 89, 32% 65 and over), 59% White and 39% Asian, 55% female, 39% ECOG PS 0 and 56% ECOG PS 1, and 58% never smokers. The disease characteristics of the overall study population were: 93% with Stage IV disease; 27% received chemotherapy in the locally advanced or metastatic setting; 14% had received CNS radiation; 31% had bone metastases; and 20% had liver metastases. CNS metastases were present in 35% (n = 96) of patients; 41 of those patients had measurable CNS lesions. ALTA 1L demonstrated a statistically significant improvement in PFS by BIRC. Efficacy results from this study are described in Table 7 and Figure 1. Table 7: Efficacy Results by BIRC Assessment in ALTA 1L Efficacy Parameters ALUNBRIG N = 137 Crizotinib N = 138 CI = Confidence Interval, NE = Not Estimable Progression-Free Survival Number of Events, n (%) 63 (46%) 87 (63%) Median (months) (95% CI) 24.0 (18.5, NE) 11.0 (9.2, 12.9) Hazard ratio (95% CI) 0.49 (0.35, 0.68) p-value Stratified by presence of iCNS metastases at baseline and prior chemotherapy for locally advanced or metastatic disease for log-rank test and Cochran Mantel-Haenszel test, respectively <.0001 Tumor Responses Confirmed Overall Response Rate, % (95% CI) 74% (66, 81) 62% (53, 70) p-value 0.0342 Complete Response, % (95% CI) 15% (9, 22) 9% (5, 15) Partial Response, % (95% CI) 59% (50, 67) 53% (44, 61) Duration of Response Number of Confirmed responders n=101 n=85 Median (months) (95% CI) Based on final analysis data for confirmed responders observed at interim analysis 33.1 (22.0, NE) 13.8 (10.4, 20.8) Figure 1: Kaplan-Meier Plot of Progression-Free Survival by BIRC in ALTA 1L At the final analysis of overall survival, conducted approximately 3 years after the last patient enrolled, there were 92 deaths (33% of all patients) including 41 deaths on the ALUNBRIG arm and 51 deaths on the crizotinib arm; median OS was not reached on either arm. BIRC assessment of confirmed intracranial ORR and intracranial DOR according to RECIST v1.1 in the subgroup of 41 patients with measurable CNS metastases (≥10 mm in longest diameter) at baseline are summarized in Table 8. Duration of intracranial response was measured from date of first intracranial response until intracranial disease progression (new lesions, intracranial target lesion diameter growth ≥20% from nadir, or unequivocal progression of intracranial nontarget lesions) or death. Table 8: Intracranial Overall Response in Patients with Measurable CNS Metastases in ALTA 1L Efficacy Parameter ALUNBRIG (N = 18) Crizotinib (N = 23) CI = Confidence Interval; NE = Not Estimable Confirmed Intracranial Overall Response Rate, (95% CI) 78% (52, 94) 26% (10, 48) Complete Response, % (95% CI) 28% (10, 53) 0 (0, 15) Partial Response, % (95% CI) 50% (26, 74) 26% (10, 48) Duration of Intracranial Response Number of Confirmed Responders n = 14 n = 6 Intracranial Response Duration ≥24 months 64% NE Figure 1 ALK-positive Advanced or Metastatic NSCLC Previously Treated with Crizotinib The efficacy of ALUNBRIG was demonstrated in a two-arm, open-label, multicenter trial (ALTA, NCT02094573) in adult patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who had progressed on crizotinib. The study required patients to have a documented ALK rearrangement based on an FDA-approved test or a different test with adequate archival tissue to confirm ALK arrangement by the Vysis ® ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit test. Key eligibility criteria included an ECOG Performance Status of 0-2 and progression on crizotinib. Neurologically stable patients with central nervous system (CNS) metastases were permitted to enroll. Patients with a history of interstitial lung disease or drug-related pneumonitis or who had received crizotinib within 3 days of the first dose of brigatinib were excluded. The major efficacy outcome measure was confirmed overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as evaluated by an Independent Review Committee (IRC). Additional efficacy outcome measures included Investigator-assessed ORR, duration of response (DOR), intracranial ORR, and intracranial DOR. A total of 222 patients were randomized to receive ALUNBRIG either 90 mg once daily (90 mg arm; n = 112) or 180 mg once daily following a 7-day lead-in at 90 mg once daily (90→180 mg arm; n = 110). Randomization was stratified by CNS metastases (present vs absent) and best prior response to crizotinib (complete or partial response vs any other response/unevaluable). Baseline demographic characteristics of the overall study population were: median age 54 years (range: 18 to 82, 23% 65 and over), 67% White and 31% Asian, 57% female, 36% ECOG PS 0 and 57% ECOG PS 1, and 95% never or former smokers. The disease characteristics of the overall study population were: Stage IV disease in 98%, adenocarcinoma histology in 97%, prior systemic chemotherapy in 74%, CNS metastases in 69% (61% had received prior CNS radiation), bone metastases in 39%, and liver metastases in 26% of patients. Sixty-four percent of patients had an objective response to prior crizotinib. The median duration of follow-up was 8 months (range: 0.1 to 20.2). Efficacy results from ALTA are summarized in Table 9. Table 9: ALTA Efficacy Results Efficacy Parameter IRC Assessment Investigator Assessment 90 mg once daily (N = 112) 90→180 mg once daily (N = 110) 90 mg once daily (N = 112) 90→180 mg once daily (N = 110) CI = Confidence Interval; NE = Not Estimable Overall Response Rate (95% CI) 48% (39,58) 53% (43,62) 45% (35,54) 54% (44,63) Complete Response, n (%) 4 (3.6%) 5 (4.5%) 1 (0.9%) 4 (3.6%) Partial Response, n (%) 50 (45%) 53 (48%) 49 (44%) 55 (50%) Duration of Response, median in months (95% CI) 13.8 (7.4,NE) 13.8 (9.3,NE) 13.8 (5.6,13.8) 11.1 (9.2,13.8) IRC assessment of intracranial ORR and intracranial DOR according to RECIST v1.1 in the subgroup of 44 patients with measurable CNS metastases (≥10 mm in longest diameter) at baseline are summarized in Table 10. Duration of intracranial response was measured from date of first intracranial response until intracranial disease progression (new lesions, intracranial target lesion diameter growth ≥20% from nadir, or unequivocal progression of intracranial nontarget lesions) or death. Table 10: Intracranial Overall Response in Patients with Measurable CNS Metastases in ALTA Efficacy Parameter IRC Assessment 90 mg once daily (N = 26) 90→180 mg once daily (N = 18) CI = Confidence Interval Intracranial Overall Response Rate, (95 % CI) 42% (23,63) 67% (41,87) Complete Response, n (%) 2 (7.7%) 0 Partial Response, n (%) 9 (35%) 12 (67%) Duration of Intracranial Response Number of Responders 11 12 Intracranial Response Duration ≥6 months 7 (64%) 6 (50%) Intracranial Response Duration ≥12 months 4 (36%) 3 (25%)"],"pharmacodynamics":["12.2 Pharmacodynamics Brigatinib exposure-response relationships and the time course of the pharmacodynamic response are unknown. Cardiac Electrophysiology The QT interval prolongation potential of ALUNBRIG was assessed in 123 patients following once daily ALUNBRIG doses of 30 mg (0.16 times the recommended dose of 180 mg) to 240 mg (1.3 times the recommended dose of 180 mg). ALUNBRIG did not prolong the QT interval to a clinically relevant extent."],"pharmacokinetics":["12.3 Pharmacokinetics The geometric mean (CV%) steady-state maximum concentration (C max ) of brigatinib at ALUNBRIG doses of 90 mg and 180 mg once daily was 552 (49%) ng/mL and 1452 (60%) ng/mL, respectively, and the corresponding area under the concentration-time curve (AUC 0-Tau ) was 8165 (45%) ng∙h/mL and 20276 (62%) ng∙h/mL. After a single dose and multiple dosing of ALUNBRIG, systemic exposure of brigatinib was dose proportional over the dose range of 60 mg (0.3 times the recommended dose of 180 mg) to 240 mg (1.3 times the recommended dose of 180 mg) once daily. The mean accumulation ratio after repeat dosing was 1.9 to 2.4. Absorption Following administration of single oral doses of ALUNBRIG of 30 mg to 240 mg, the median time to peak concentration (T max ) ranged from 1 to 4 hours. Effect of Food Brigatinib C max was reduced by 13% with no effect on AUC in healthy subjects administered ALUNBRIG after a high fat meal (approximately 920 calories, 58 grams carbohydrate, 59 grams fat and 40 grams protein) compared to the C max and AUC after overnight fasting. Distribution Brigatinib is 91% bound to human plasma proteins and the binding is not concentration-dependent. The blood-to-plasma concentration ratio is 0.69. Following oral administration of ALUNBRIG 180 mg once daily, the mean apparent volume of distribution (V z/ F) of brigatinib at steady-state was 307 L. Elimination Following oral administration of ALUNBRIG 180 mg once daily, the mean apparent oral clearance (CL/F) of brigatinib at steady-state is 8.9 L/h and the mean plasma elimination half-life is 25 hours. Metabolism Brigatinib is primarily metabolized by CYP2C8 and CYP3A4 in vitro . Following oral administration of a single 180 mg dose of radiolabeled brigatinib to healthy subjects, N-demethylation and cysteine conjugation were the two major metabolic pathways. Unchanged brigatinib (92%) was the major circulating radioactive component. Excretion Following oral administration of a single 180 mg dose of radiolabeled brigatinib to healthy subjects, 65% of the administered dose was recovered in feces and 25% of the administered dose was recovered in urine. Unchanged brigatinib represented 41% and 86% of the total radioactivity in feces and urine, respectively. Specific Populations Age, race, sex, body weight, and albumin concentration have no clinically meaningful effect on the pharmacokinetics of brigatinib. Patients with Hepatic Impairment Following a single dose of ALUNBRIG 90 mg, unbound brigatinib systemic exposure (AUC 0-INF ) was 37% higher in subjects with severe hepatic impairment (Child-Pugh C) compared to subjects with normal hepatic function. Unbound brigatinib systemic exposure (AUC 0-INF ) was similar between subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment and subjects with normal hepatic function [see Dosage and Administration (2.6) ] . Patients with Renal Impairment Following a single dose of ALUNBRIG 90 mg, unbound brigatinib systemic exposure (AUC 0-INF ) was 86% higher in subjects with severe renal impairment [creatinine clearance (CLcr) 15 to 29 mL/min] compared to subjects with normal renal function. Based on a population pharmacokinetic analysis, brigatinib exposures were similar among 125 subjects with mild renal impairment (CLcr 60 to 89 mL/min), 34 subjects with moderate renal impairment (CLcr 30 to 59 mL/min) and 270 subjects with normal renal function (CLcr ≥90 mL/min) [see Dosage and Administration (2.7) ] . Drug Interaction Studies Clinical Studies Effect of Strong and Moderate CYP3A Inhibitors on Brigatinib: Coadministration of 200 mg twice daily doses of itraconazole (a strong CYP3A inhibitor) with a single 90 mg dose of ALUNBRIG increased brigatinib C max by 21% and AUC 0-INF by 101%, relative to a 90 mg dose of ALUNBRIG administered alone [see Dosage and Administration (2.4) , Drug Interactions (7.1) ] . A moderate CYP3A inhibitor is predicted to increase the AUC of brigatinib by approximately 40%. Effect of Strong CYP2C8 Inhibitors on Brigatinib: Coadministration of 600 mg twice daily doses of gemfibrozil (a strong CYP2C8 inhibitor) with a single 90 mg dose of ALUNBRIG decreased brigatinib C max by 41% and AUC 0-INF by 12%, relative to a 90 mg dose of ALUNBRIG administered alone. The effect of gemfibrozil on the pharmacokinetics of brigatinib is not clinically meaningful and the underlying mechanism for the decreased exposure of brigatinib is unknown. Effect of Strong and Moderate CYP3A Inducers on Brigatinib: Coadministration of 600 mg daily doses of rifampin (a strong CYP3A inducer) with a single 180 mg dose of ALUNBRIG decreased brigatinib C max by 60% and AUC 0-INF by 80%, relative to a 180 mg dose of ALUNBRIG administered alone [see Dosage and Administration (2.5) , Drug Interactions (7.1) ] . A moderate CYP3A inducer is predicted to decrease the AUC of brigatinib by approximately 50%. Effect of Brigatinib on CYP3A Substrates: Coadministration of 180 mg daily doses of ALUNBRIG with a single 3 mg oral dose of midazolam (a sensitive CYP3A substrate) decreased midazolam C max by 16% and AUC 0-INF by 26%, relative to a 3 mg oral dose of midazolam administered alone. Brigatinib is considered a weak inducer of CYP3A. In Vitro Studies Effect of Brigatinib on CYP Enzymes: Brigatinib, at clinically relevant plasma concentrations, induced CYP3A via activation of the pregnane X receptor (PXR). Brigatinib may also induce CYP2C enzymes via the same mechanism at clinically relevant concentrations. Brigatinib did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5 at clinically relevant concentrations. Effect of P-glycoprotein and BCRP Inhibitors on Brigatinib: Brigatinib is a substrate of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Given that brigatinib exhibits high solubility and high permeability in vitro , P-gp and BCRP inhibitors are unlikely to increase plasma concentrations of brigatinib. Effect of Other Transporters on Brigatinib: Brigatinib is not a substrate of organic anion transporting polypeptide (OATP1B1, OATP1B3), organic anion transporter (OAT1, OAT3), organic cation transporter (OCT1, OCT2), multidrug and toxin extrusion protein (MATE1, MATE2K), or bile salt export pump (BSEP). Effect of Brigatinib on Transporters: Brigatinib is an inhibitor of P-gp, BCRP, OCT1, MATE1, and MATE2K in vitro . Therefore, brigatinib may have the potential to increase concentrations of coadministered substrates of these transporters. Brigatinib at clinically relevant concentrations did not inhibit OATP1B1, OATP1B3, OAT1, OAT3, OCT2 or BSEP."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the prescribing information: Interstitial Lung Disease (ILD)/Pneumonitis [see Warnings and Precautions (5.1) ] Hypertension [see Warnings and Precautions (5.2) ] Bradycardia [see Warnings and Precautions (5.3) ] Visual Disturbance [see Warnings and Precautions (5.4) ] Creatine Phosphokinase (CPK) Elevation [see Warnings and Precautions (5.5) ] Pancreatic Enzymes Elevation [see Warnings and Precautions (5.6) ] Hepatotoxicity [see Warnings and Precautions (5.7) ] Hyperglycemia [see Warnings and Precautions (5.8) ] Photosensitivity [see Warnings and Precautions (5.9) ] The most common adverse reactions (≥25%) with ALUNBRIG were diarrhea, fatigue, nausea, rash, cough, myalgia, headache, hypertension, vomiting, and dyspnea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-217-6468 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Advanced ALK-positive NSCLC Without Prior ALK-targeted Therapy In ALTA 1L, the safety of ALUNBRIG was evaluated in 136 patients with advanced ALK-positive NSCLC who had not previously received an ALK-targeted therapy [see Clinical Studies (14) ] . The median duration of treatment with ALUNBRIG when administered as 90 mg orally once daily for the first 7 days; then increased to 180 mg orally once daily, was 24.3 months. A total of 106 (78%) patients were exposed to ALUNBRIG for greater than or equal to 6 months including 92 (68%) patients exposed for greater than or equal to 1 year. The median relative dose intensity was 97% for ALUNBRIG. The study population (N = 275) characteristics were: median age 59 years (range: 27 to 89), age less than 65 years (68%), female (55%), White (59%), Asian (39%), Stage IV disease (93%), NSCLC adenocarcinoma histology (96%), never smoker (58%), ECOG Performance Status (PS) 0 or 1 (95%), and CNS metastases at baseline (30%) [see Clinical Studies (14) ] . Serious adverse reactions occurred in 33% of patients receiving ALUNBRIG. The most common serious adverse reactions were pneumonia (4.4%), ILD/pneumonitis (3.7%), pyrexia (2.9%), dyspnea (2.2%), pulmonary embolism (2.2%), and asthenia (2.2%). Fatal adverse reactions occurred in 2.9% of patients and included pneumonia (1.5%), cerebrovascular accident (0.7%), and multiple organ dysfunction syndrome (0.7%). In ALTA 1L, 13% of patients receiving ALUNBRIG permanently discontinued ALUNBRIG for adverse reactions. The most frequent adverse reactions that led to discontinuation were ILD/pneumonitis (3.7%) and pneumonia (2.2%). In ALTA 1L, 38% of patients required a dose reduction due to adverse reactions. The most common adverse reaction that led to dose reduction was increased creatine phosphokinase (15%), increased lipase (6.6%), increased amylase (4.4%), increased aspartate aminotransferase (2.2%), ILD/pneumonitis (2.2%) and hypertension (2.2%). Table 3 and Table 4 summarize the common adverse reactions and laboratory abnormalities observed in ALTA 1L. Table 3: Adverse Reactions in ≥10% (All Grades Per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 ) or ≥2% (Grades 3-4) of Patients by Arm in ALTA 1L (N = 273) Adverse Reactions ALUNBRIG N = 136 Crizotinib N = 137 All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Gastrointestinal Disorders Diarrhea 53 2.2 57 2.9 Nausea 30 2.2 58 2.9 Abdominal pain Includes abdominal discomfort, abdominal distension, abdominal pain, abdominal pain lower, abdominal pain upper, and epigastric discomfort 24 0.7 33 3.6 Vomiting 21 0.7 44 2.2 Constipation 18 0 42 0 Stomatitis Includes aphthous ulcer, mouth ulceration, oral mucosal blistering and stomatitis 13 0.7 8.8 0 Dyspepsia 8 0 16 0.7 Gastroesophageal reflux disease 0.7 0 11 0 Skin and Subcutaneous Tissue Disorders Rash Includes dermatitis, dermatitis acneiform, dermatitis bullous, dermatitis contact, drug eruption, erythema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, toxic skin eruption, urticaria 40 2.9 17 0 Pruritus Included pruritus, allergic pruritus, and generalized pruritus 20 0.7 5.8 0.7 Respiratory, Thoracic and Mediastinal Disorders Cough 35 0 20 0 Dyspnea Include dyspnea and exertional dyspnea 25 2.9 22 Includes Grade 5 events 3.6 ILD/Pneumonitis 5.1 2.9 2.2 0.7 Pulmonary embolism 2.2 2.2 5.8 2.9 Vascular Disorders Hypertension Includes hypertension and systolic hypertension 32 13 8 2.9 General Disorders and Administration Site Conditions Fatigue Includes asthenia and fatigue 32 1.5 40 2.2 Edema Includes angioedema, eye swelling, eyelid edema, face edema, generalized edema, lip swelling, peripheral edema, periorbital edema, peripheral swelling, skin swelling, swelling and swelling face 18 0.7 48 0.7 Pyrexia 15 0.7 15 0 Musculoskeletal and Connective Tissue Disorders Myalgia Includes muscle spasms, muscle twitching, musculoskeletal discomfort, musculoskeletal pain, and myalgia 28 0 23 0 Back pain 21 0.7 17 1.5 Arthralgia 14 0 12 0 Pain in extremity 5.1 0 15 0.7 Nervous System Disorders Headache Includes headache and migraine 22 2.2 17 0 Dizziness 15 0.7 20 0.7 Peripheral neuropathy Includes burning sensation, dysesthesia, hyperesthesia, hypoesthesia, neuralgia, peripheral neuropathy, paraesthesia, peripheral sensory neuropathy and polyneuropathy 11 0.7 18 0 Dysgeusia 2.9 0 14 0 Investigations Increased Blood cholesterol Includes blood cholesterol increased, hypercholesterolaemia 13 0 0.7 0 Cardiac Disorders Bradycardia Includes bradycardia, heart rate decreased, sinus bradycardia 12 0.7 23 0 Infections and Infestations Pneumonia Includes lower respiratory tract infection, lung infection, pneumonia, aspiration pneumonia, and cryptococcal pneumonia 15 5.1 6.6 2.9 Upper respiratory tract infection Includes upper respiratory tract infection and viral upper respiratory tract infection 12 0 10 0 Nasopharyngitis 8 0 11 0 Urinary tract infection 5.9 0.7 8.8 2.2 Metabolism and Nutrition Disorders Decreased Appetite 8.8 0.7 19 2.9 Eye Disorders Visual Disturbance Includes cataract, glaucoma, hypermetropia, night blindness, papilloedema, photophobia, photopsia, blurred vision, reduced visual acuity, visual field defect, visual impairment, and vitreous floaters 7.4 0 53 0.7 Table 4: Laboratory Abnormalities in ≥20% (All Grades Per CTCAE version 4.03 ) of Patients by Arm in ALTA 1L (N = 273) Laboratory Abnormality ALUNBRIG N = 136 Denominator for each laboratory parameter may vary and is defined as the number of patients who had both, baseline and post-baseline test Crizotinib N = 137 All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Chemistry Increased creatine phosphokinase 81 24 68 4.8 Increased aspartate aminotransferase 72 4.5 70 5.2 Increased lipase 59 17 36 9.8 Hyperglycemia Elevated blood insulin was also observed in both arms 56 7.5 37 3.7 Increased alanine aminotransferase 52 5.2 77 13 Increased amylase 52 6.8 25 3 Decreased phosphorous 41 3.7 39 6 Increased alkaline phosphatase 36 3 49 1.5 Increased creatinine 25 0 33 0 Potassium increased 24 1.5 31 3.7 Increased calcium 22 0 1.5 0 Decreased magnesium 21 0 6.9 0 Decreased albumin 15 0.8 52 3.7 Decreased calcium 15 0 67 1.5 Hematology Hemoglobin decreased 41 2.3 36 1.5 Lymphocyte count decreased 42 9.3 30 5.4 Neutrophil count decreased 12 0 34 6.8 Clinically relevant adverse reactions in patients who received ALUNBRIG included photosensitivity (3.7%). ALK-positive Advanced or Metastatic NSCLC Previously Treated with Crizotinib The safety of ALUNBRIG was evaluated in 219 patients with locally advanced or metastatic ALK-positive NSCLC who received at least 1 dose of ALUNBRIG in ALTA after experiencing disease progression on crizotinib. Patients received ALUNBRIG 90 mg once daily continuously (90 mg group) or 90 mg once daily for 7 days followed by 180 mg once daily (90→180 mg group). The median duration of treatment was 7.5 months in the 90 mg group and 7.8 months in the 90→180 mg group. A total of 150 (68%) patients were exposed to ALUNBRIG for greater than or equal to 6 months and 42 (19%) patients were exposed for greater than or equal to 1 year. The study population (N = 222) characteristics were: median age 54 years (range: 18 to 82), age less than 65 years (77%), female (57%), White (67%), Asian (31%), Stage IV disease (98%), NSCLC adenocarcinoma histology (97%), never or former smoker (95%), ECOG Performance Status (PS) 0 or 1 (93%), and CNS metastases at baseline (69%) [see Clinical Studies (14) ] . Serious adverse reactions occurred in 38% of patients in the 90 mg group and 40% of patients in the 90→180 mg group. The most common serious adverse reactions were pneumonia (5.5% overall, 3.7% in the 90 mg group, and 7.3% in the 90→180 mg group) and ILD/pneumonitis (4.6% overall, 1.8% in the 90 mg group and 7.3% in the 90→180 mg group). Fatal adverse reactions occurred in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis (1 patient each). In ALTA, 2.8% of patients in the 90 mg group and 8.2% of patients in the 90→180 mg group permanently discontinued ALUNBRIG for adverse reactions. The most frequent adverse reactions that led to discontinuation were ILD/pneumonitis (0.9% in the 90 mg group and 1.8% in the 90→180 mg group) and pneumonia (1.8% in the 90→180 mg group only). In ALTA, 14% of patients required a dose reduction due to adverse reactions (7.3% in the 90 mg group and 20% in the 90→180 mg group). The most common adverse reaction that led to dose reduction was increased creatine phosphokinase for both regimens (1.8% in the 90 mg group and 4.5% in the 90→180 mg group). Table 5 and Table 6 summarize the common adverse reactions and laboratory abnormalities observed in ALTA. Table 5: Adverse Reactions in ≥10% (All Grades Per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 ) or ≥2% (Grades 3-4) of Patients by Dose Group in ALTA (N = 219) Adverse Reactions 90 mg once daily N = 109 90→180 mg once daily N = 110 All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Gastrointestinal Disorders Nausea 33 0.9 40 0.9 Diarrhea 19 0 38 0 Vomiting 24 1.8 23 0 Constipation 19 0.9 15 0 Abdominal Pain Includes abdominal distension, abdominal pain, and epigastric discomfort 17 0 10 0 General Disorders and Administration Site Conditions Fatigue Includes asthenia and fatigue 29 1.8 36 0 Pyrexia 14 0 6.4 0.9 Respiratory, Thoracic and Mediastinal Disorders Cough 18 0 34 0 Dyspnea Includes dyspnea and exertional dyspnea 27 2.8 21 1.8 Includes one Grade 5 event ILD/Pneumonitis 3.7 1.8 9.1 2.7 Hypoxia 0.9 0 2.7 2.7 Nervous System Disorders Headache Includes headache and sinus headache 28 0 27 0.9 Peripheral Neuropathy Includes peripheral sensory neuropathy and paresthesia 13 0.9 13 1.8 Skin and Subcutaneous Tissue Disorders Rash Includes acneiform dermatitis, exfoliative rash, rash, pruritic rash, and pustular rash 15 1.8 24 3.6 Vascular Disorders Hypertension 11 5.5 21 6.4 Musculoskeletal and Connective Tissue Disorders Muscle Spasms 12 0 17 0 Back pain 10 1.8 15 1.8 Myalgia Includes musculoskeletal pain and myalgia 9.2 0 15 0.9 Arthralgia 14 0.9 14 0 Pain in extremity 11 0 3.6 0.9 Metabolism and Nutrition Disorders Decreased Appetite 22 0.9 15 0.9 Eye Disorders Visual Disturbance Includes diplopia, photophobia, blurred vision, reduced visual acuity, visual impairment, vitreous floaters, visual field defect, macular edema, and vitreous detachment 7.3 0 10 0.9 Infections Pneumonia 4.6 2.8 10 5.5 Psychiatric Disorders Insomnia 11 0 7.3 0 Table 6: Laboratory Abnormalities in ≥20% (All Grades Per CTCAE version 4.0 ) of Patients by Regimen in ALTA (N = 219) Laboratory Abnormality 90 mg once daily N = 109 90→180 mg once daily N = 110 All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) Chemistry Increased aspartate aminotransferase 38 0.9 65 0 Hyperglycemia Elevated blood insulin was observed in both regimens 38 3.7 49 3.6 Increased creatine phosphokinase 27 2.8 48 12 Increased lipase 21 4.6 45 5.5 Increased alanine aminotransferase 34 0 40 2.7 Increased amylase 27 3.7 39 2.7 Increased alkaline phosphatase 15 0.9 29 0.9 Decreased phosphorous 15 1.8 23 3.6 Prolonged activated partial thromboplastin time 22 1.8 20 0.9 Hematology Anemia 23 0.9 40 0.9 Lymphopenia 19 2.8 27 4.5 Clinically relevant adverse reactions in patients who received ALUNBRIG included photosensitivity (0.9%). Other Adverse Reactions from Multiple Clinical Trials In a pooled clinical trial population consisting of three studies with 274 patients treated with ALUNBRIG at the recommended dose, the following adverse reactions and laboratory abnormalities were reported: white blood cell count decreased (28%), hyponatremia (20%), hypokalemia (19%), decreased platelet count (10%), dry skin (4.7%), pain (3.3%), and musculoskeletal stiffness (1.1%)."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS CYP3A Inhibitors : Avoid coadministration of ALUNBRIG with strong or moderate CYP3A inhibitors. If coadministration of a strong or moderate CYP3A inhibitor is unavoidable, reduce the dose of ALUNBRIG. ( 2.4 , 7.1 ) CYP3A Inducers : Avoid coadministration of ALUNBRIG with strong or moderate CYP3A inducers. If coadministration of a moderate CYP3A inducer is unavoidable, increase the dose of ALUNBRIG. ( 2.5 , 7.1 ) 7.1 Effect of Other Drugs on ALUNBRIG Strong or Moderate CYP3A Inhibitors Coadministration of ALUNBRIG with a strong or moderate CYP3A inhibitor increased brigatinib plasma concentrations, which may increase the incidence of adverse reactions [see Clinical Pharmacology (12.3) ] . Avoid coadministration of ALUNBRIG with strong or moderate CYP3A inhibitors. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, modify dose as recommended [see Dosage and Administration (2.4) ] . Strong or Moderate CYP3A Inducers Coadministration of ALUNBRIG with a strong or moderate CYP3A inducer decreased brigatinib plasma concentrations, which may decrease the efficacy of ALUNBRIG [see Clinical Pharmacology (12.3) ] . Avoid coadministration of ALUNBRIG with strong or moderate CYP3A inducers. If coadministration of moderate CYP3A inducers cannot be avoided, modify dose as recommended [see Dosage and Administration (2.5) ] ."],"how_supplied_table":["
Bottle of 23 tabletsNDC 63020-180-23
Bottle of 30 tabletsNDC 63020-180-30
","
Bottle of 7 tabletsNDC 63020-090-07
Bottle of 30 tabletsNDC 63020-090-30
","
Bottle of 30 tabletsNDC 63020-113-30
","
One carton containing one bottle of 90 mg tablets (7 count) and one bottle of 180 mg tablets (23 count)NDC 63020-198-30
"],"mechanism_of_action":["12.1 Mechanism of Action Brigatinib is a tyrosine kinase inhibitor (TKI) with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays. Brigatinib also inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice. At clinically achievable concentrations (≤500 nM), brigatinib inhibited the in vitro viability of cells expressing EML4-ALK and 17 mutant forms associated with resistance to ALK inhibitors including crizotinib, as well as EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. Brigatinib exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including G1202R and L1196M mutants identified in NSCLC tumors in patients who have progressed on crizotinib. Brigatinib also reduced tumor burden and prolonged survival in mice implanted intracranially with an ALK-driven tumor cell line."],"storage_and_handling":["Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) (see USP)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Brigatinib is a tyrosine kinase inhibitor (TKI) with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays. Brigatinib also inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice. At clinically achievable concentrations (≤500 nM), brigatinib inhibited the in vitro viability of cells expressing EML4-ALK and 17 mutant forms associated with resistance to ALK inhibitors including crizotinib, as well as EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. Brigatinib exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including G1202R and L1196M mutants identified in NSCLC tumors in patients who have progressed on crizotinib. Brigatinib also reduced tumor burden and prolonged survival in mice implanted intracranially with an ALK-driven tumor cell line. 12.2 Pharmacodynamics Brigatinib exposure-response relationships and the time course of the pharmacodynamic response are unknown. Cardiac Electrophysiology The QT interval prolongation potential of ALUNBRIG was assessed in 123 patients following once daily ALUNBRIG doses of 30 mg (0.16 times the recommended dose of 180 mg) to 240 mg (1.3 times the recommended dose of 180 mg). ALUNBRIG did not prolong the QT interval to a clinically relevant extent. 12.3 Pharmacokinetics The geometric mean (CV%) steady-state maximum concentration (C max ) of brigatinib at ALUNBRIG doses of 90 mg and 180 mg once daily was 552 (49%) ng/mL and 1452 (60%) ng/mL, respectively, and the corresponding area under the concentration-time curve (AUC 0-Tau ) was 8165 (45%) ng∙h/mL and 20276 (62%) ng∙h/mL. After a single dose and multiple dosing of ALUNBRIG, systemic exposure of brigatinib was dose proportional over the dose range of 60 mg (0.3 times the recommended dose of 180 mg) to 240 mg (1.3 times the recommended dose of 180 mg) once daily. The mean accumulation ratio after repeat dosing was 1.9 to 2.4. Absorption Following administration of single oral doses of ALUNBRIG of 30 mg to 240 mg, the median time to peak concentration (T max ) ranged from 1 to 4 hours. Effect of Food Brigatinib C max was reduced by 13% with no effect on AUC in healthy subjects administered ALUNBRIG after a high fat meal (approximately 920 calories, 58 grams carbohydrate, 59 grams fat and 40 grams protein) compared to the C max and AUC after overnight fasting. Distribution Brigatinib is 91% bound to human plasma proteins and the binding is not concentration-dependent. The blood-to-plasma concentration ratio is 0.69. Following oral administration of ALUNBRIG 180 mg once daily, the mean apparent volume of distribution (V z/ F) of brigatinib at steady-state was 307 L. Elimination Following oral administration of ALUNBRIG 180 mg once daily, the mean apparent oral clearance (CL/F) of brigatinib at steady-state is 8.9 L/h and the mean plasma elimination half-life is 25 hours. Metabolism Brigatinib is primarily metabolized by CYP2C8 and CYP3A4 in vitro . Following oral administration of a single 180 mg dose of radiolabeled brigatinib to healthy subjects, N-demethylation and cysteine conjugation were the two major metabolic pathways. Unchanged brigatinib (92%) was the major circulating radioactive component. Excretion Following oral administration of a single 180 mg dose of radiolabeled brigatinib to healthy subjects, 65% of the administered dose was recovered in feces and 25% of the administered dose was recovered in urine. Unchanged brigatinib represented 41% and 86% of the total radioactivity in feces and urine, respectively. Specific Populations Age, race, sex, body weight, and albumin concentration have no clinically meaningful effect on the pharmacokinetics of brigatinib. Patients with Hepatic Impairment Following a single dose of ALUNBRIG 90 mg, unbound brigatinib systemic exposure (AUC 0-INF ) was 37% higher in subjects with severe hepatic impairment (Child-Pugh C) compared to subjects with normal hepatic function. Unbound brigatinib systemic exposure (AUC 0-INF ) was similar between subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment and subjects with normal hepatic function [see Dosage and Administration (2.6) ] . Patients with Renal Impairment Following a single dose of ALUNBRIG 90 mg, unbound brigatinib systemic exposure (AUC 0-INF ) was 86% higher in subjects with severe renal impairment [creatinine clearance (CLcr) 15 to 29 mL/min] compared to subjects with normal renal function. Based on a population pharmacokinetic analysis, brigatinib exposures were similar among 125 subjects with mild renal impairment (CLcr 60 to 89 mL/min), 34 subjects with moderate renal impairment (CLcr 30 to 59 mL/min) and 270 subjects with normal renal function (CLcr ≥90 mL/min) [see Dosage and Administration (2.7) ] . Drug Interaction Studies Clinical Studies Effect of Strong and Moderate CYP3A Inhibitors on Brigatinib: Coadministration of 200 mg twice daily doses of itraconazole (a strong CYP3A inhibitor) with a single 90 mg dose of ALUNBRIG increased brigatinib C max by 21% and AUC 0-INF by 101%, relative to a 90 mg dose of ALUNBRIG administered alone [see Dosage and Administration (2.4) , Drug Interactions (7.1) ] . A moderate CYP3A inhibitor is predicted to increase the AUC of brigatinib by approximately 40%. Effect of Strong CYP2C8 Inhibitors on Brigatinib: Coadministration of 600 mg twice daily doses of gemfibrozil (a strong CYP2C8 inhibitor) with a single 90 mg dose of ALUNBRIG decreased brigatinib C max by 41% and AUC 0-INF by 12%, relative to a 90 mg dose of ALUNBRIG administered alone. The effect of gemfibrozil on the pharmacokinetics of brigatinib is not clinically meaningful and the underlying mechanism for the decreased exposure of brigatinib is unknown. Effect of Strong and Moderate CYP3A Inducers on Brigatinib: Coadministration of 600 mg daily doses of rifampin (a strong CYP3A inducer) with a single 180 mg dose of ALUNBRIG decreased brigatinib C max by 60% and AUC 0-INF by 80%, relative to a 180 mg dose of ALUNBRIG administered alone [see Dosage and Administration (2.5) , Drug Interactions (7.1) ] . A moderate CYP3A inducer is predicted to decrease the AUC of brigatinib by approximately 50%. Effect of Brigatinib on CYP3A Substrates: Coadministration of 180 mg daily doses of ALUNBRIG with a single 3 mg oral dose of midazolam (a sensitive CYP3A substrate) decreased midazolam C max by 16% and AUC 0-INF by 26%, relative to a 3 mg oral dose of midazolam administered alone. Brigatinib is considered a weak inducer of CYP3A. In Vitro Studies Effect of Brigatinib on CYP Enzymes: Brigatinib, at clinically relevant plasma concentrations, induced CYP3A via activation of the pregnane X receptor (PXR). Brigatinib may also induce CYP2C enzymes via the same mechanism at clinically relevant concentrations. Brigatinib did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5 at clinically relevant concentrations. Effect of P-glycoprotein and BCRP Inhibitors on Brigatinib: Brigatinib is a substrate of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Given that brigatinib exhibits high solubility and high permeability in vitro , P-gp and BCRP inhibitors are unlikely to increase plasma concentrations of brigatinib. Effect of Other Transporters on Brigatinib: Brigatinib is not a substrate of organic anion transporting polypeptide (OATP1B1, OATP1B3), organic anion transporter (OAT1, OAT3), organic cation transporter (OCT1, OCT2), multidrug and toxin extrusion protein (MATE1, MATE2K), or bile salt export pump (BSEP). Effect of Brigatinib on Transporters: Brigatinib is an inhibitor of P-gp, BCRP, OCT1, MATE1, and MATE2K in vitro . Therefore, brigatinib may have the potential to increase concentrations of coadministered substrates of these transporters. Brigatinib at clinically relevant concentrations did not inhibit OATP1B1, OATP1B3, OAT1, OAT3, OCT2 or BSEP."],"indications_and_usage":["1 INDICATIONS AND USAGE ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening respiratory symptoms, particularly during the first week of treatment. Withhold ALUNBRIG for new or worsening respiratory symptoms and promptly evaluate for ILD/pneumonitis. Upon recovery, either dose reduce or permanently discontinue ALUNBRIG. ( 2.3 , 5.1 ) Hypertension : Monitor blood pressure after 2 weeks and then at least monthly during treatment. For severe hypertension, withhold ALUNBRIG, then dose reduce or permanently discontinue. ( 2.3 , 5.2 ) Bradycardia : Monitor heart rate and blood pressure regularly during treatment. If symptomatic, withhold ALUNBRIG, then dose reduce or permanently discontinue. ( 2.3 , 5.3 ) Visual Disturbance : Advise patients to report visual symptoms. Withhold ALUNBRIG and obtain ophthalmologic evaluation, then dose reduce or permanently discontinue ALUNBRIG. ( 2.3 , 5.4 ) Creatine Phosphokinase (CPK) Elevation : Monitor CPK levels regularly during treatment. Based on the severity and with muscle pain or weakness, withhold ALUNBRIG, then resume or reduce dose. ( 2.3 , 5.5 ) Pancreatic Enzymes Elevation : Monitor lipase and amylase levels regularly during treatment. Based on the severity, withhold ALUNBRIG, then resume or reduce dose. ( 2.3 , 5.6 ) Hepatotoxicity : Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin levels regularly during treatment. Based on severity, withhold dose, then resume at lower level. ( 2.3 , 5.7 ) Hyperglycemia : Assess fasting serum glucose prior to starting ALUNBRIG and regularly during treatment. If not adequately controlled with optimal medical management, withhold ALUNBRIG, then consider dose reduction or permanently discontinue, based on severity. ( 2.3 , 5.8 ) Photosensitivity : Advise patients to limit sun exposure. Based on severity withhold ALUNBRIG, then resume at the same dose, reduce the dose, or permanently discontinue. ( 2.3 , 5.9 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.10 , 8.1 , 8.3 ) 5.1 Interstitial Lung Disease (ILD)/Pneumonitis Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG. In Trial ALTA 1L, ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG. ILD/pneumonitis occurred within 8 days of initiation of ALUNBRIG in 2.9% of patients, with Grade 3 to 4 reactions occurring in 2.2% of patients. In Trial ALTA, ILD/pneumonitis occurred in 3.7% of patients in the 90 mg group (90 mg once daily) and 9.1% of patients in the 90→180 mg group (180 mg once daily with 7-day lead-in at 90 mg once daily). Adverse reactions consistent with possible ILD/pneumonitis occurred within 9 days of initiation of ALUNBRIG (median onset was 2 days) in 6.4% of patients, with Grade 3 to 4 reactions occurring in 2.7%. Monitor for new or worsening respiratory symptoms (e.g., dyspnea, cough, etc.), particularly during the first week of initiating ALUNBRIG. Withhold ALUNBRIG in any patient with new or worsening respiratory symptoms, and promptly evaluate for ILD/pneumonitis or other causes of respiratory symptoms (e.g., pulmonary embolism, tumor progression, and infectious pneumonia). For Grade 1 or 2 ILD/pneumonitis, either resume ALUNBRIG with dose reduction according to Table 1 after recovery to baseline or permanently discontinue ALUNBRIG. Permanently discontinue ALUNBRIG for Grade 3 or 4 ILD/pneumonitis or recurrence of Grade 1 or 2 ILD/pneumonitis [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . 5.2 Hypertension In ALTA 1L, hypertension was reported in 32% of patients receiving ALUNBRIG; Grade 3 hypertension occurred in 13% of patients. In ALTA, hypertension was reported in 11% of patients in the 90 mg group who received ALUNBRIG and 21% of patients in the 90→180 mg group. Grade 3 hypertension occurred in 5.9% of patients overall. Control blood pressure prior to treatment with ALUNBRIG. Monitor blood pressure after 2 weeks and at least monthly thereafter during treatment with ALUNBRIG. Withhold ALUNBRIG for Grade 3 hypertension despite optimal antihypertensive therapy. Upon resolution or improvement to Grade 1, resume ALUNBRIG at the same dose. Consider permanent discontinuation of treatment with ALUNBRIG for Grade 4 hypertension or recurrence of Grade 3 hypertension [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . Use caution when administering ALUNBRIG in combination with antihypertensive agents that cause bradycardia [see Warnings and Precautions (5.3) ] . 5.3 Bradycardia In ALTA 1L, heart rates less than 50 beats per minute (bpm) occurred in 8.1% of patients receiving ALUNBRIG. Grade 3 bradycardia occurred in 1 patient (0.7%). In ALTA, heart rates less than 50 beats per minute (bpm) occurred in 5.7% of patients in the 90 mg group and 7.6% of patients in the 90→180 mg group. Grade 2 bradycardia occurred in 1 (0.9%) patient in the 90 mg group. Monitor heart rate and blood pressure during treatment with ALUNBRIG. Monitor patients more frequently if concomitant use of drug known to cause bradycardia cannot be avoided [see Warnings and Precautions (5.2) ] . For symptomatic bradycardia, withhold ALUNBRIG and review concomitant medications for those known to cause bradycardia. If a concomitant medication known to cause bradycardia is identified and discontinued or dose adjusted, resume ALUNBRIG at the same dose following resolution of symptomatic bradycardia; otherwise, reduce the dose of ALUNBRIG following resolution of symptomatic bradycardia. Discontinue ALUNBRIG for life-threatening bradycardia if no contributing concomitant medication is identified [see Dosage and Administration (2.3) ] . 5.4 Visual Disturbance In ALTA 1L, Grade 1 or 2 adverse reactions leading to visual disturbance including blurred vision, photophobia, photopsia, and reduced visual acuity were reported in 7.4% of patients receiving ALUNBRIG. In ALTA, adverse reactions leading to visual disturbance including blurred vision, diplopia, and reduced visual acuity, were reported in 7.3% of patients receiving ALUNBRIG in the 90 mg group and 10% of patients in the 90→180 mg group. Grade 3 macular edema and cataract occurred in 1 patient each in the 90→180 mg group. Advise patients to report any visual symptoms. Withhold ALUNBRIG and obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms of Grade 2 or greater severity. Upon recovery of Grade 2 or Grade 3 visual disturbances to Grade 1 severity or baseline, resume ALUNBRIG at a reduced dose. Permanently discontinue treatment with ALUNBRIG for Grade 4 visual disturbances [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . 5.5 Creatine Phosphokinase (CPK) Elevation In ALTA 1L, creatine phosphokinase (CPK) elevation occurred in 81% of patients who received ALUNBRIG. The incidence of Grade 3 or 4 CPK elevation was 24%. Dose reduction for CPK elevation occurred in 15% of patients. In ALTA, CPK elevation occurred in 27% of patients receiving ALUNBRIG in the 90 mg group and 48% of patients in the 90 mg→180 mg group. The incidence of Grade 3 to 4 CPK elevation was 2.8% in the 90 mg group and 12% in the 90→180 mg group. Dose reduction for CPK elevation occurred in 1.8% of patients in the 90 mg group and 4.5% in the 90→180 mg group. Advise patients to report any unexplained muscle pain, tenderness, or weakness. Monitor CPK levels during ALUNBRIG treatment. Withhold ALUNBRIG for Grade 3 or 4 CPK elevation with Grade 2 or higher muscle pain or weakness. Upon resolution or recovery to Grade 1 CPK elevation or baseline, resume ALUNBRIG at the same dose or at a reduced dose as described in Table 2 [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . 5.6 Pancreatic Enzymes Elevation In ALTA 1L, amylase elevation occurred in 52% of patients and Grade 3 or 4 amylase elevation occurred in 6.8% of patients. Lipase elevations occurred in 59% of patients and Grade 3 or 4 lipase elevation occurred in 17% of patients. In ALTA, amylase elevation occurred in 27% of patients in the 90 mg group and 39% of patients in the 90→180 mg group. Lipase elevations occurred in 21% of patients in the 90 mg group and 45% of patients in the 90→180 mg group. Grade 3 or 4 amylase elevation occurred in 3.7% of patients in the 90 mg group and 2.7% of patients in the 90→180 mg group. Grade 3 or 4 lipase elevation occurred in 4.6% of patients in the 90 mg group and 5.5% of patients in the 90→180 mg group. Monitor lipase and amylase during treatment with ALUNBRIG. Withhold ALUNBRIG for Grade 3 or 4 pancreatic enzyme elevation. Upon resolution or recovery to Grade 1 or baseline, resume ALUNBRIG at the same dose or at a reduced dose as described in Table 2 [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . 5.7 Hepatotoxicity In ALTA 1L, aspartate aminotransferase (AST) elevations occurred in 72% of patients and Grade 3 or 4 AST elevations occurred in 4.5% of patients. Alanine aminotransferase (ALT) elevations occurred in 52% of patients and Grade 3 or 4 ALT elevations occurred in 5.2% of patients. One patient (0.7%) had a serious adverse reaction of hepatocellular injury. In ALTA, AST elevations occurred in 38% of patients in the 90 mg group and 65% of patients in the 90→180 mg group. ALT elevations occurred in 34% of patients in the 90 mg group and 40% of patients in the 90→180 mg group. Grade 3 or 4 AST elevations occurred in 0.9% of patients in the 90 mg group and did not occur in any patients in the 90→180 mg group. Grade 3 or 4 ALT elevations did not occur in any patients in the 90 mg group and in 2.7% of patients in the 90→180 mg group. Monitor AST, ALT and total bilirubin during treatment with ALUNBRIG, especially during first 3 months. Withhold ALUNBRIG for Grade 3 or 4 hepatic enzyme elevation with bilirubin less than or equal to 2 × ULN. Upon resolution or recovery to Grade 1 or less (less than or equal to 3 × ULN) or to baseline, resume ALUNBRIG at a next lower dose as described in Table 2. Permanently discontinue ALUNBRIG for Grade 2 to 4 hepatic enzyme elevation with concurrent total bilirubin elevation greater than 2 times the ULN in the absence of cholestasis or hemolysis [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . 5.8 Hyperglycemia In ALTA 1L, 56% of patients who received ALUNBRIG experienced new or worsening hyperglycemia. Grade 3 hyperglycemia, based on laboratory assessment of serum fasting glucose levels, occurred in 7.5% of patients. In ALTA, 43% of patients who received ALUNBRIG experienced new or worsening hyperglycemia. Grade 3 hyperglycemia, based on laboratory assessment of serum fasting glucose levels, occurred in 3.7% of patients. Two of 20 (10%) patients with diabetes or glucose intolerance at baseline required initiation of insulin while receiving ALUNBRIG. Assess fasting serum glucose prior to initiation of ALUNBRIG and monitor periodically thereafter. Initiate or optimize antihyperglycemic medications as needed. If adequate hyperglycemic control cannot be achieved with optimal medical management, withhold ALUNBRIG until adequate hyperglycemic control is achieved and consider reducing the dose of ALUNBRIG as described in Table 1 or permanently discontinuing ALUNBRIG [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . 5.9 Photosensitivity In ALTA 1L, photosensitivity occurred in 3.7% of patients who received ALUNBRIG, with 0.7% Grade 3 to 4. In ALTA, 0.9% of patients who received ALUNBRIG in the 90 mg group experienced photosensitivity and 0.9% of patients in the 90 mg→180 mg group. Grade 3 to 4 photosensitivity was not reported in patients in the 90 mg group or in the 90→180 mg group. Advise patients to limit sun exposure while taking brigatinib, and for at least 5 days after discontinuation of treatment. Advise patients, when outdoors to wear a hat and protective clothing, and use a broad-spectrum Ultraviolet A (UVA)/ Ultraviolet B (UVB) sunscreen and lip balm (SPF ≥30) to help protect against sunburn. Based on the severity withhold ALUNBRIG, then resume at the same dose, or reduce the dose, or permanently discontinue as described in Table 2 [see Dosage and Administration (2.3) , Adverse Reactions (6.1) ] . 5.10 Embryo-Fetal Toxicity Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to pregnant women. There are no clinical data on the use of ALUNBRIG in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily), as well as increased post-implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or higher. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 4 months following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose of ALUNBRIG [see Use in Specific Populations (8.1 , 8.3) , Clinical Pharmacology (12.1) ] ."],"clinical_studies_table":["
Table 7: Efficacy Results by BIRC Assessment in ALTA 1L
Efficacy ParametersALUNBRIG N = 137Crizotinib N = 138
CI = Confidence Interval, NE = Not Estimable
Progression-Free Survival
Number of Events, n (%)63 (46%)87 (63%)
Median (months) (95% CI)24.0 (18.5, NE)11.0 (9.2, 12.9)
Hazard ratio (95% CI)0.49 (0.35, 0.68)
p-valueStratified by presence of iCNS metastases at baseline and prior chemotherapy for locally advanced or metastatic disease for log-rank test and Cochran Mantel-Haenszel test, respectively<.0001
Tumor Responses
Confirmed Overall Response Rate, % (95% CI)74% (66, 81)62% (53, 70)
p-value0.0342
Complete Response, % (95% CI)15% (9, 22)9% (5, 15)
Partial Response, % (95% CI)59% (50, 67)53% (44, 61)
Duration of Response
Number of Confirmed respondersn=101n=85
Median (months) (95% CI) Based on final analysis data for confirmed responders observed at interim analysis33.1 (22.0, NE)13.8 (10.4, 20.8)
","
Table 8: Intracranial Overall Response in Patients with Measurable CNS Metastases in ALTA 1L
Efficacy ParameterALUNBRIG (N = 18)Crizotinib (N = 23)
CI = Confidence Interval; NE = Not Estimable
Confirmed Intracranial Overall Response Rate, (95% CI)78% (52, 94)26% (10, 48)
Complete Response, % (95% CI)28% (10, 53)0 (0, 15)
Partial Response, % (95% CI)50% (26, 74)26% (10, 48)
Duration of Intracranial Response
Number of Confirmed Respondersn = 14n = 6
Intracranial Response Duration ≥24 months64%NE
","
Table 9: ALTA Efficacy Results
Efficacy ParameterIRC AssessmentInvestigator Assessment
90 mg once daily (N = 112)90→180 mg once daily (N = 110)90 mg once daily (N = 112)90→180 mg once daily (N = 110)
CI = Confidence Interval; NE = Not Estimable
Overall Response Rate (95% CI)48% (39,58)53% (43,62)45% (35,54)54% (44,63)
Complete Response, n (%)4 (3.6%)5 (4.5%)1 (0.9%)4 (3.6%)
Partial Response, n (%)50 (45%)53 (48%)49 (44%)55 (50%)
Duration of Response, median in months (95% CI)13.8 (7.4,NE)13.8 (9.3,NE)13.8 (5.6,13.8)11.1 (9.2,13.8)
","
Table 10: Intracranial Overall Response in Patients with Measurable CNS Metastases in ALTA
Efficacy ParameterIRC Assessment
90 mg once daily (N = 26)90→180 mg once daily (N = 18)
CI = Confidence Interval
Intracranial Overall Response Rate, (95 % CI)42% (23,63)67% (41,87)
Complete Response, n (%)2 (7.7%)0
Partial Response, n (%)9 (35%)12 (67%)
Duration of Intracranial Response
Number of Responders1112
Intracranial Response Duration ≥6 months7 (64%)6 (50%)
Intracranial Response Duration ≥12 months4 (36%)3 (25%)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with brigatinib. Treatment with brigatinib resulted in chromosomal damage in an in vivo mammalian erythrocyte micronucleus in the rat, but was not mutagenic in the Ames or in vitro mammalian chromosome aberration tests. Dedicated animal fertility studies were not conducted with brigatinib. Testicular toxicity was observed in repeat-dose animal studies at doses resulting in exposure as low as 0.2 times the exposure in patients at the 180 mg dose. In rats, findings included lower weight of testes, seminal vesicles and prostate gland, and testicular tubular degeneration; these effects were not reversible during the 2 month recovery period. In monkeys, findings included reduced size of testes along with microscopic evidence of hypospermatogenesis; these effects were reversible during the recovery period."],"adverse_reactions_table":["
Table 3: Adverse Reactions in ≥10% (All GradesPer National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03) or ≥2% (Grades 3-4) of Patients by Arm in ALTA 1L (N = 273)
Adverse ReactionsALUNBRIG N = 136Crizotinib N = 137
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Gastrointestinal Disorders
Diarrhea532.2572.9
Nausea302.2582.9
Abdominal painIncludes abdominal discomfort, abdominal distension, abdominal pain, abdominal pain lower, abdominal pain upper, and epigastric discomfort240.7333.6
Vomiting210.7442.2
Constipation180420
StomatitisIncludes aphthous ulcer, mouth ulceration, oral mucosal blistering and stomatitis130.78.80
Dyspepsia80160.7
Gastroesophageal reflux disease0.70110
Skin and Subcutaneous Tissue Disorders
RashIncludes dermatitis, dermatitis acneiform, dermatitis bullous, dermatitis contact, drug eruption, erythema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, toxic skin eruption, urticaria402.9170
PruritusIncluded pruritus, allergic pruritus, and generalized pruritus200.75.80.7
Respiratory, Thoracic and Mediastinal Disorders
Cough350200
DyspneaInclude dyspnea and exertional dyspnea252.922Includes Grade 5 events3.6
ILD/Pneumonitis5.12.92.20.7
Pulmonary embolism2.22.25.82.9
Vascular Disorders
Hypertension Includes hypertension and systolic hypertension321382.9
General Disorders and Administration Site Conditions
FatigueIncludes asthenia and fatigue321.5402.2
EdemaIncludes angioedema, eye swelling, eyelid edema, face edema, generalized edema, lip swelling, peripheral edema, periorbital edema, peripheral swelling, skin swelling, swelling and swelling face180.7480.7
Pyrexia150.7150
Musculoskeletal and Connective Tissue Disorders
MyalgiaIncludes muscle spasms, muscle twitching, musculoskeletal discomfort, musculoskeletal pain, and myalgia280230
Back pain210.7171.5
Arthralgia140120
Pain in extremity5.10150.7
Nervous System Disorders
HeadacheIncludes headache and migraine222.2170
Dizziness150.7200.7
Peripheral neuropathyIncludes burning sensation, dysesthesia, hyperesthesia, hypoesthesia, neuralgia, peripheral neuropathy, paraesthesia, peripheral sensory neuropathy and polyneuropathy110.7180
Dysgeusia2.90140
Investigations
Increased Blood cholesterolIncludes blood cholesterol increased, hypercholesterolaemia1300.70
Cardiac Disorders
BradycardiaIncludes bradycardia, heart rate decreased, sinus bradycardia120.7230
Infections and Infestations
PneumoniaIncludes lower respiratory tract infection, lung infection, pneumonia, aspiration pneumonia, and cryptococcal pneumonia155.16.62.9
Upper respiratory tract infectionIncludes upper respiratory tract infection and viral upper respiratory tract infection120100
Nasopharyngitis80110
Urinary tract infection5.90.78.82.2
Metabolism and Nutrition Disorders
Decreased Appetite8.80.7192.9
Eye Disorders
Visual DisturbanceIncludes cataract, glaucoma, hypermetropia, night blindness, papilloedema, photophobia, photopsia, blurred vision, reduced visual acuity, visual field defect, visual impairment, and vitreous floaters7.40530.7
","
Table 4: Laboratory Abnormalities in ≥20% (All GradesPer CTCAE version 4.03) of Patients by Arm in ALTA 1L (N = 273)
Laboratory AbnormalityALUNBRIG N = 136Denominator for each laboratory parameter may vary and is defined as the number of patients who had both, baseline and post-baseline testCrizotinib N = 137
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Chemistry
Increased creatine phosphokinase8124684.8
Increased aspartate aminotransferase724.5705.2
Increased lipase5917369.8
HyperglycemiaElevated blood insulin was also observed in both arms567.5373.7
Increased alanine aminotransferase525.27713
Increased amylase526.8253
Decreased phosphorous413.7396
Increased alkaline phosphatase363491.5
Increased creatinine250330
Potassium increased241.5313.7
Increased calcium2201.50
Decreased magnesium2106.90
Decreased albumin150.8523.7
Decreased calcium150671.5
Hematology
Hemoglobin decreased412.3361.5
Lymphocyte count decreased429.3305.4
Neutrophil count decreased120346.8
","
Table 5: Adverse Reactions in ≥10% (All GradesPer National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0) or ≥2% (Grades 3-4) of Patients by Dose Group in ALTA (N = 219)
Adverse Reactions90 mg once daily N = 10990→180 mg once daily N = 110
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Gastrointestinal Disorders
Nausea330.9400.9
Diarrhea190380
Vomiting241.8230
Constipation190.9150
Abdominal PainIncludes abdominal distension, abdominal pain, and epigastric discomfort170100
General Disorders and Administration Site Conditions
FatigueIncludes asthenia and fatigue291.8360
Pyrexia1406.40.9
Respiratory, Thoracic and Mediastinal Disorders
Cough180340
DyspneaIncludes dyspnea and exertional dyspnea272.8211.8Includes one Grade 5 event
ILD/Pneumonitis3.71.89.12.7
Hypoxia0.902.72.7
Nervous System Disorders
HeadacheIncludes headache and sinus headache280270.9
Peripheral NeuropathyIncludes peripheral sensory neuropathy and paresthesia130.9131.8
Skin and Subcutaneous Tissue Disorders
RashIncludes acneiform dermatitis, exfoliative rash, rash, pruritic rash, and pustular rash151.8243.6
Vascular Disorders
Hypertension115.5216.4
Musculoskeletal and Connective Tissue Disorders
Muscle Spasms120170
Back pain101.8151.8
MyalgiaIncludes musculoskeletal pain and myalgia9.20150.9
Arthralgia140.9140
Pain in extremity1103.60.9
Metabolism and Nutrition Disorders
Decreased Appetite220.9150.9
Eye Disorders
Visual DisturbanceIncludes diplopia, photophobia, blurred vision, reduced visual acuity, visual impairment, vitreous floaters, visual field defect, macular edema, and vitreous detachment7.30100.9
Infections
Pneumonia4.62.8105.5
Psychiatric Disorders
Insomnia1107.30
","
Table 6: Laboratory Abnormalities in ≥20% (All GradesPer CTCAE version 4.0) of Patients by Regimen in ALTA (N = 219)
Laboratory Abnormality90 mg once daily N = 10990→180 mg once daily N = 110
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
Chemistry
Increased aspartate aminotransferase380.9650
HyperglycemiaElevated blood insulin was observed in both regimens383.7493.6
Increased creatine phosphokinase272.84812
Increased lipase214.6455.5
Increased alanine aminotransferase340402.7
Increased amylase273.7392.7
Increased alkaline phosphatase150.9290.9
Decreased phosphorous151.8233.6
Prolonged activated partial thromboplastin time221.8200.9
Hematology
Anemia230.9400.9
Lymphopenia192.8274.5
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Interstitial Lung Disease (ILD)/Pneumonitis Inform patients of the symptoms and risks of serious pulmonary adverse reactions such as ILD/pneumonitis. Advise patients to immediately report any new or worsening respiratory symptoms [see Warnings and Precautions (5.1) ] . Hypertension Advise patients of risks of hypertension and to promptly report signs or symptoms of hypertension [see Warnings and Precautions (5.2) ] . Bradycardia Advise patients to report any symptoms of bradycardia and to inform their healthcare provider about the use of heart and blood pressure medications [see Warnings and Precautions (5.3) ] . Visual Disturbance Advise patients to inform their healthcare provider of any new or worsening vision symptoms [see Warnings and Precautions (5.4) ] . Creatine Phosphokinase (CPK) Elevation Inform patients of the signs and symptoms of creatine phosphokinase (CPK) elevation and the need for monitoring during treatment. Advise patients to inform their healthcare provider of any new or worsening symptoms [see Warnings and Precautions (5.5) ] . Pancreatic Enzymes Elevation Inform patients of the signs and symptoms of pancreatitis and the need to monitor for amylase and lipase elevations during treatment [see Warnings and Precautions (5.6) ] . Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity, and the need to monitor for aspartate aminotransferase (AST), alanine animotransferase (ALT) and total bilirubin elevations during treatment. Advise patients to inform their healthcare provider of any new or worsening symptoms [see Warnings and Precautions (5.7) ] . Hyperglycemia Inform patients of the risks of new or worsening hyperglycemia and the need to periodically monitor glucose levels. Advise patients with diabetes mellitus or glucose intolerance that antihyperglycemic medications may need to be adjusted during treatment with ALUNBRIG [see Warnings and Precautions (5.8) ] . Photosensitivit y Inform patients of the signs and symptoms of photosensitivity. Advise patients to limit sun exposure while taking ALUNBRIG and for at least 5 days after the final dose. Advise patients to wear a hat, protective clothing, and to use a broad-spectrum Ultraviolet A (UVA)/ Ultraviolet B (UVB) sunscreen and lip balm (SPF ≥30) to protect against sunburn [see Warnings and Precautions (5.9) ] . Females and Males of Reproductive Potential Embryo-Fetal Toxicity Advise females and males of reproductive potential that ALUNBRIG can cause fetal harm [see Warnings and Precautions (5.10) , Use in Specific Populations (8.1) ] . Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy and to use effective contraception during treatment with ALUNBRIG and for at least 4 months after the final dose [see Use in Specific Populations (8.3) ] . Advise males with female partners of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 3 months after the final dose [see Use in Specific Populations (8.3) ] . Lactation Advise females not to breastfeed during treatment with ALUNBRIG and for at least 1 week following the final dose [see Use in Specific Populations (8.2) ] . Infertility Advise males of reproductive potential of the potential for reduced fertility from ALUNBRIG [see Use in Specific Populations (8.3) , Nonclinical Toxicology (13.1) ] . Drug Interactions Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid grapefruit or grapefruit juice while taking ALUNBRIG [see Drug Interactions (7) ] . Dosing and Administration Instruct patients to start with 90 mg of ALUNBRIG once daily for the first 7 days and if tolerated, increase the dose to 180 mg once daily. Advise patients to take ALUNBRIG with or without food [see Dosage and Administration (2.2) ] . Missed Dose Advise patients that if a dose of ALUNBRIG is missed or if the patient vomits after taking a dose of ALUNBRIG, not to take an extra dose, but to take the next dose at the regular time [see Dosage and Administration (2.2) ] ."],"spl_unclassified_section":["Distributed by: Takeda Pharmaceuticals America, Inc. Cambridge, MA 02142 ALUNBRIG and are registered trademarks of ARIAD Pharmaceuticals, Inc. ©2024 ARIAD Pharmaceuticals, Inc. All rights reserved. ABG346 R6 logo"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food. ( 2.2 ) 2.1 Patient Selection Select patients for the treatment of metastatic NSCLC with ALUNBRIG based on the presence of ALK positivity in tumor specimens [see Clinical Studies (14) ] . Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage The recommended dosage for ALUNBRIG is: 90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily. Administer ALUNBRIG until disease progression or unacceptable toxicity. If ALUNBRIG is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose. ALUNBRIG may be taken with or without food. Instruct patients to swallow tablets whole. Do not crush or chew tablets. If a dose of ALUNBRIG is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose of ALUNBRIG at the scheduled time. 2.3 Dosage Modifications for Adverse Reactions ALUNBRIG dosage reductions for adverse reactions are summarized in Table 1. Table 1: Recommended ALUNBRIG Dosage Reductions Dosage Reduction Dosage First Second Third 90 mg once daily 60 mg once daily permanently discontinue N/A Not applicable 180 mg once daily 120 mg once daily 90 mg once daily 60 mg once daily Once reduced for adverse reactions, do not subsequently increase the dosage of ALUNBRIG. Permanently discontinue ALUNBRIG if patients are unable to tolerate the 60 mg once daily dose. Recommendations for dosage modifications of ALUNBRIG for the management of adverse reactions are provided in Table 2. Table 2: Recommended ALUNBRIG Dosage Modifications for Adverse Reactions Adverse Reaction Severity Graded per National Cancer Institute Common Terminology Criteria for Adverse Events. Version 4.0 (NCI CTCAE v4). Dosage Modifications bpm = beats per minute; DBP = diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure; ULN = upper limit of normal Interstitial Lung Disease (ILD) /Pneumonitis [see Warnings and Precautions (5.1 )] Grade 1 If new pulmonary symptoms occur during the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline, then resume at same dose and do not escalate to 180 mg if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline, then resume at same dose. If ILD/pneumonitis recurs, permanently discontinue ALUNBRIG. Grade 2 If new pulmonary symptoms occur during the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline. Resume at next lower dose (Table 1) and do not dose escalate if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline. If ILD/pneumonitis is suspected, resume at next lower dose (Table 1); otherwise, resume at same dose. If ILD/pneumonitis recurs, permanently discontinue ALUNBRIG. Grade 3 or 4 Permanently discontinue ALUNBRIG for ILD/pneumonitis. Hypertension [see Warnings and Precautions (5.2) ] Grade 3 hypertension (SBP greater than or equal to 160 mmHg or DBP greater than or equal to 100 mmHg, medical intervention indicated, more than one antihypertensive drug, or more intensive therapy than previously used indicated) Withhold ALUNBRIG until hypertension has recovered to Grade 1 or less (SBP less than 140 mmHg and DBP less than 90 mmHg), then resume ALUNBRIG at the same dose. Recurrence: withhold ALUNBRIG until recovery to Grade 1 or less, and resume at next lower dose (Table 1) or permanently discontinue treatment. Grade 4 hypertension (life-threatening consequences, urgent intervention indicated) Withhold ALUNBRIG until recovery to Grade 1 or less, and resume at next lower dose (Table 1) or permanently discontinue treatment. Recurrence: permanently discontinue ALUNBRIG for recurrence of Grade 4 hypertension. Bradycardia (HR less than 60 bpm) [see Warnings and Precautions (5.3) ] Symptomatic bradycardia Withhold ALUNBRIG until recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above. If a concomitant medication known to cause bradycardia is identified and discontinued or dose-adjusted, resume ALUNBRIG at same dose upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above. If no concomitant medication known to cause bradycardia is identified, or if contributing concomitant medications are not discontinued or dose-adjusted, resume ALUNBRIG at next lower dose (Table 1) upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above. Bradycardia with life-threatening consequences, urgent intervention indicated Permanently discontinue ALUNBRIG if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued or dose-adjusted, resume ALUNBRIG at next lower dose (Table 1) upon recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above, with frequent monitoring as clinically indicated. Recurrence: permanently discontinue ALUNBRIG. Visual Disturbance [see Warnings and Precautions (5.4) ] Grade 2 or 3 visual disturbance Withhold ALUNBRIG until recovery to Grade 1 or baseline, then resume at the next lower dose (Table 1). Grade 4 visual disturbance Permanently discontinue ALUNBRIG. Creatine Phosphokinase (CPK) Elevation [see Warnings and Precautions (5.5) ] Grade 3 or 4 CPK elevation (greater than 5× ULN) with Grade 2 or higher muscle pain or weakness Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 2.5× ULN) CPK elevation or to baseline, then resume ALUNBRIG at same dose. Recurrence: Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 2.5× ULN) CPK elevation or to baseline, then resume ALUNBRIG at the next lower dose (Table 1). Lipase/Amylase Elevation [see Warnings and Precautions (5.6) ] Grade 3 lipase or amylase elevation (greater than 2× ULN) Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 1.5× ULN) or to baseline, then resume ALUNBRIG at same dose. Recurrence: Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 1.5× ULN) or to baseline, then resume ALUNBRIG at next lower dose (Table 1). Grade 4 lipase or amylase elevation (greater than 5× ULN) Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 1.5× ULN) or to baseline, then resume ALUNBRIG at next lower dose (Table 1). Hepatotoxicity (Elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)) [see Warnings and Precautions (5.7) ] Grade 3 or 4 elevation (greater than 5 × ULN) of either ALT or AST with bilirubin less than or equal to 2 × ULN Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 3× ULN) or to baseline, then resume ALUNBRIG at next lower dose (Table 1). Grade 2 to 4 elevation (greater than 3 × ULN) of ALT or AST with concurrent total bilirubin elevation greater than 2 × ULN in the absence of cholestasis or hemolysis Permanently discontinue ALUNBRIG. Hyperglycemia [see Warnings and Precautions (5.8) ] Grade 3 (greater than 250 mg/dL or 13.9 mmol/L) or 4 If adequate hyperglycemic control cannot be achieved with optimal medical management, withhold ALUNBRIG until adequate hyperglycemic control is achieved and resume at the next lower dose (Table 1) or permanently discontinue ALUNBRIG. Other Grade 3 Withhold ALUNBRIG until recovery to baseline, then resume at same dose. Recurrence: withhold ALUNBRIG until recovery to baseline, then resume at next lower dose or discontinue ALUNBRIG (Table 1). Grade 4 Withhold ALUNBRIG until recovery to baseline and resume at next lower dose (Table 1). Recurrence: Permanently discontinue ALUNBRIG. 2.4 Dosage Modifications for Strong or Moderate CYP3A Inhibitors Avoid coadministration of strong or moderate CYP3A inhibitors during treatment with ALUNBRIG [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] . If coadministration of a strong CYP3A inhibitor cannot be avoided, reduce the ALUNBRIG once daily dose by approximately 50% (i.e., from 180 mg to 90 mg, or from 90 mg to 60 mg). If coadministration of a moderate CYP3A inhibitor cannot be avoided, reduce the ALUNBRIG once daily dose by approximately 40% (i.e., from 180 mg to 120 mg, 120 mg to 90 mg, or from 90 mg to 60 mg). After discontinuation of a strong or moderate CYP3A inhibitor, resume the ALUNBRIG dose that was tolerated prior to initiating the CYP3A inhibitor. 2.5 Dosage Modifications for Moderate CYP3A Inducers Avoid coadministration of moderate CYP3A inducers during treatment with ALUNBRIG [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] . If coadministration of a moderate CYP3A inducer cannot be avoided, increase the ALUNBRIG once daily dose in 30 mg increments after 7 days of treatment with the current ALUNBRIG dose as tolerated, up to a maximum of twice the ALUNBRIG dose that was tolerated prior to initiating the moderate CYP3A inducer. After discontinuation of a moderate CYP3A inducer, resume the ALUNBRIG dose that was tolerated prior to initiating the moderate CYP3A inducer. 2.6 Dosage Modifications for Patients with Severe Hepatic Impairment Reduce the ALUNBRIG once daily dose by approximately 40% (i.e., from 180 mg to 120 mg, 120 mg to 90 mg, or from 90 mg to 60 mg) for patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ] . 2.7 Dosage Modifications for Patients with Severe Renal Impairment Reduce the ALUNBRIG once daily dose by approximately 50% (i.e., from 180 mg to 90 mg, or from 90 mg to 60 mg) for patients with severe renal impairment [creatinine clearance (CLcr) 15 to 29 mL/min by Cockcroft-Gault] [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] ."],"spl_product_data_elements":["Alunbrig brigatinib brigatinib brigatinib Lactose monohydrate Microcrystalline cellulose SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE Magnesium stearate U3 Alunbrig brigatinib brigatinib brigatinib Lactose monohydrate Microcrystalline cellulose SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE Magnesium stearate U7 Alunbrig brigatinib brigatinib brigatinib Lactose monohydrate Microcrystalline cellulose SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE Magnesium stearate U13 Alunbrig brigatinib Alunbrig brigatinib brigatinib brigatinib Lactose monohydrate Microcrystalline cellulose SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE Magnesium stearate U7 Alunbrig brigatinib brigatinib brigatinib Lactose monohydrate Microcrystalline cellulose SODIUM STARCH GLYCOLATE TYPE A POTATO SILICON DIOXIDE Magnesium stearate U13"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS 180 mg: oval, white to off-white film-coated tablets with \"U13\" debossed on one side and plain on the other side 90 mg: oval, white to off-white film-coated tablets with \"U7\" debossed on one side and plain on the other side 30 mg: round, white to off-white film-coated tablets with \"U3\" debossed on one side and plain on the other side Tablets: 180 mg, 90 mg, or 30 mg. ( 3 )"],"spl_patient_package_insert":["PATIENT INFORMATION ALUNBRIG ® (uh-lun-brig) (brigatinib) tablets This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: October 2024 What is the most important information I should know about ALUNBRIG? ALUNBRIG can cause serious side effects, including: Lung problems. ALUNBRIG may cause severe or life-threatening swelling (inflammation) of the lungs any time during treatment, and can lead to death. These lung problems happen especially within the first week of treatment with ALUNBRIG. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms, including: trouble breathing or shortness of breath chest pain cough with or without mucus fever High blood pressure (hypertension). ALUNBRIG may cause high blood pressure. Your healthcare provider will check your blood pressure before starting and during treatment with ALUNBRIG. Tell your healthcare provider right away if you get headaches, dizziness, blurred vision, chest pain or shortness of breath. Slow heart rate (bradycardia). ALUNBRIG may cause very slow heartbeats that can be severe. Your healthcare provider will check your heart rate during treatment with ALUNBRIG. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint during treatment with ALUNBRIG. Tell your healthcare provider if you take any heart or blood pressure medicines. Vision problems. ALUNBRIG may cause vision problems. Your healthcare provider may stop ALUNBRIG and refer you to an eye specialist if you develop severe vision problems during treatment with ALUNBRIG. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including: double vision seeing flashes of light blurry vision light hurting your eyes new or increased floaters Muscle pain, tenderness, and weakness (myalgia). ALUNBRIG may increase the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Your healthcare provider will do blood tests to check your blood levels of CPK during treatment with ALUNBRIG. Tell your healthcare provider right away if you get new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness. Inflammation of the pancreas (pancreatitis). ALUNBRIG may increase enzymes in your blood called amylase and lipase, which may be a sign of pancreatitis. Your healthcare provider will do blood tests to check your pancreatic enzyme blood levels during treatment with ALUNBRIG. Tell your healthcare provider right away if you get new or worsening signs and symptoms of pancreatitis, including upper abdominal pain that may spread to the back and get worse with eating, weight loss, or nausea. Liver problems (hepatotoxicity). ALUNBRIG may increase the levels of bilirubin in your blood and enzymes called aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in your blood, which may be a sign of liver problems. Your healthcare provider will do blood tests to check your liver during treatment with ALUNBRIG. Tell your healthcare provider right away if you get new or worsening signs or symptoms, including: yellowing of your skin or the white part of your eyes dark or brown (tea color) urine nausea or vomiting pain on the right side of your stomach area bleed or bruise more easily than normal itchy skin decreased appetite feeling tired High blood sugar (hyperglycemia). ALUNBRIG may increase your blood sugar levels. Your healthcare provider will do blood tests to check your blood sugar levels before starting and during treatment with ALUNBRIG. Your healthcare provider may need to start or change your blood sugar medicine to control your blood sugar levels. Tell your healthcare provider right away if you get new or worsening signs and symptoms of hyperglycemia, including: feeling very thirsty needing to urinate more than usual feeling very hungry feeling sick to your stomach feeling weak or tired feeling confused See \" What are the possible side effects of ALUNBRIG? \" for information about side effects. What is ALUNBRIG? ALUNBRIG is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC): that has a certain type of abnormal anaplastic lymphoma kinase (ALK) gene, and that has spread to other parts of your body. It is not known if ALUNBRIG is safe and effective in children. Before you take ALUNBRIG, tell your healthcare provider about all of your medical conditions, including if you: have lung or breathing problems have high blood pressure have a slow heartbeat have any vision problems have or have had pancreatitis have liver problems have diabetes mellitus or glucose intolerance have kidney problems or are on dialysis are pregnant or plan to become pregnant. ALUNBRIG can harm your unborn baby. Your healthcare provider will determine whether or not you are pregnant before you start treatment with ALUNBRIG. Tell your healthcare provider right away if you become pregnant during treatment with ALUNBRIG or think you may be pregnant. Females who are able to become pregnant should use effective birth control during treatment with ALUNBRIG and for at least 4 months after the final dose of ALUNBRIG. Talk to your healthcare provider about birth control choices that are right for you during treatment with ALUNBRIG. Males who have female partners that are able to become pregnant should use effective birth control during treatment with ALUNBRIG and for at least 3 months after the final dose of ALUNBRIG. are breastfeeding or plan to breastfeed. It is not known if ALUNBRIG passes into your breast milk. Do not breastfeed during treatment with ALUNBRIG and for 1 week after the final dose of ALUNBRIG. Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. How should I take ALUNBRIG? Take ALUNBRIG exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking ALUNBRIG unless your healthcare provider tells you to. Your healthcare provider will start you on a low dose (90 mg) of ALUNBRIG for the first 7 days of treatment. If you tolerate this dose of ALUNBRIG well, your healthcare provider may increase your dose after the first 7 days of treatment. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ALUNBRIG if you develop side effects. Take ALUNBRIG 1 time each day. Take ALUNBRIG with or without food. Swallow ALUNBRIG tablets whole. Do not crush or chew tablets. If you miss a dose of ALUNBRIG, do not take the missed dose. Take your next dose at your regular time. If you vomit after taking a dose of ALUNBRIG, do not take an extra dose. Take your next dose at your regular time. What should I avoid while taking ALUNBRIG? Limit your time in the sun during treatment with ALUNBRIG and for at least 5 days after your final dose. ALUNBRIG may make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. When you are in the sun, wear a hat and protective clothing, and use a broad-spectrum sunscreen and lip balm with a Sun Protection Factor (SPF) of 30 or greater to protect against sunburn. Avoid eating grapefruit or drinking grapefruit juice during treatment with ALUNBRIG. Grapefruit may increase the amount of ALUNBRIG in your blood. What are the possible side effects of ALUNBRIG? ALUNBRIG may cause serious side effects, including: See \" What is the most important information I should know about ALUNBRIG? \". The most common side effects of ALUNBRIG include: diarrhea fatigue nausea rash cough muscle pain headache high blood pressure vomiting difficulty breathing ALUNBRIG may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility. These are not all of the possible side effects of ALUNBRIG. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store ALUNBRIG? Store ALUNBRIG at room temperature between 68°F to 77°F (20°C to 25°C). Keep ALUNBRIG and all medicines out of the reach of children. General information about the safe and effective use of ALUNBRIG. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ALUNBRIG for a condition for which it was not prescribed. Do not give ALUNBRIG to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about ALUNBRIG that is written for health professionals. What are the ingredients in ALUNBRIG? Active ingredient: brigatinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide. Distributed by: Takeda Pharmaceuticals America, Inc. , Cambridge, MA 02142 ALUNBRIG and are registered trademarks of ARIAD Pharmaceuticals, Inc. ©2024 ARIAD Pharmaceuticals, Inc. All rights reserved. For more information, go to www.alunbrig.com or call 1-844-217-6468. ABG346 R6 logo"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Hepatic Impairment : Reduce the dose of ALUNBRIG for patients with severe hepatic impairment. ( 2.6 , 8.6 ) Renal Impairment : Reduce the dose of ALUNBRIG for patients with severe renal impairment. ( 2.7 , 8.7 ) Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no clinical data on the use of ALUNBRIG in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily) as well as increased post-implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or greater (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal development study in which pregnant rats were administered daily doses of brigatinib during organogenesis, dose-related skeletal (incomplete ossification, small incisors) and visceral anomalies were observed at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily). Malformations observed at 25 mg/kg/day (approximately 1.26 times the human AUC at 180 mg once daily) included anasarca (generalized subcutaneous edema), anophthalmia (absent eyes), forelimb hyperflexion, small, short and/or bent limbs, multiple fused ribs, bent scapulae, omphalocele (intestine protruding into umbilicus), and gastroschisis (intestines protruding through a defect in the abdominal wall) along with visceral findings of moderate bilateral dilatation of the lateral ventricles. 8.2 Lactation Risk Summary There are no data regarding the secretion of brigatinib in human milk or its effects on the breastfed infant or milk production. Because of the potential for adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment with ALUNBRIG and for 1 week following the final dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating ALUNBRIG [see Use in Specific Populations (8.1) ] . Contraception ALUNBRIG can cause fetal harm [see Use in Specific Populations (8.1) ] . Females Advise females of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 4 months after the final dose. Males Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 3 months after the final dose [see Nonclinical Toxicology (13.1) ] . Infertility Based on findings in male reproductive organs in animals, ALUNBRIG may cause reduced fertility in males [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of ALUNBRIG in pediatric patients have not been established. 8.5 Geriatric Use Of the 359 patients enrolled in the ALTA 1L ALUNBRIG arm and in ALTA, 26.7% were 65 and older and 7.5% were 75 and older. No overall differences in safety or effectiveness were observed between patients ≥65 years and younger patients. 8.6 Hepatic Impairment No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A) or moderate hepatic impairment (Child-Pugh B). Reduce the dose of ALUNBRIG for patients with severe hepatic impairment (Child-Pugh C) [see Dosage and Administration (2.6) , Clinical Pharmacology (12.3) ] . 8.7 Renal Impairment No dose adjustment is recommended for patients with mild or moderate renal impairment [creatinine clearance (CLcr) 30 to 89 mL/min by Cockcroft-Gault]. Reduce the dose of ALUNBRIG for patients with severe renal impairment (CLcr 15 to 29 mL/min) [see Dosage and Administration (2.7) , Clinical Pharmacology (12.3) ] ."],"dosage_and_administration_table":["
Table 1: Recommended ALUNBRIG Dosage Reductions
Dosage Reduction
DosageFirstSecondThird
90 mg once daily60 mg once dailypermanently discontinueN/ANot applicable
180 mg once daily120 mg once daily90 mg once daily60 mg once daily
","
Table 2: Recommended ALUNBRIG Dosage Modifications for Adverse Reactions
Adverse ReactionSeverityGraded per National Cancer Institute Common Terminology Criteria for Adverse Events. Version 4.0 (NCI CTCAE v4).Dosage Modifications
bpm = beats per minute; DBP = diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure; ULN = upper limit of normal
Interstitial Lung Disease (ILD) /Pneumonitis [see Warnings and Precautions (5.1)]Grade 1If new pulmonary symptoms occur during the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline, then resume at same dose and do not escalate to 180 mg if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline, then resume at same dose.If ILD/pneumonitis recurs, permanently discontinue ALUNBRIG.
Grade 2If new pulmonary symptoms occur during the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline. Resume at next lower dose (Table 1) and do not dose escalate if ILD/pneumonitis is suspected.If new pulmonary symptoms occur after the first 7 days of treatment, withhold ALUNBRIG until recovery to baseline. If ILD/pneumonitis is suspected, resume at next lower dose (Table 1); otherwise, resume at same dose. If ILD/pneumonitis recurs, permanently discontinue ALUNBRIG.
Grade 3 or 4Permanently discontinue ALUNBRIG for ILD/pneumonitis.
Hypertension [see Warnings and Precautions (5.2)]Grade 3 hypertension (SBP greater than or equal to 160 mmHg or DBP greater than or equal to 100 mmHg, medical intervention indicated, more than one antihypertensive drug, or more intensive therapy than previously used indicated)Withhold ALUNBRIG until hypertension has recovered to Grade 1 or less (SBP less than 140 mmHg and DBP less than 90 mmHg), then resume ALUNBRIG at the same dose.Recurrence: withhold ALUNBRIG until recovery to Grade 1 or less, and resume at next lower dose (Table 1) or permanently discontinue treatment.
Grade 4 hypertension (life-threatening consequences, urgent intervention indicated)Withhold ALUNBRIG until recovery to Grade 1 or less, and resume at next lower dose (Table 1) or permanently discontinue treatment.Recurrence: permanently discontinue ALUNBRIG for recurrence of Grade 4 hypertension.
Bradycardia (HR less than 60 bpm) [see Warnings and Precautions (5.3)]Symptomatic bradycardiaWithhold ALUNBRIG until recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above.If a concomitant medication known to cause bradycardia is identified and discontinued or dose-adjusted, resume ALUNBRIG at same dose upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above.If no concomitant medication known to cause bradycardia is identified, or if contributing concomitant medications are not discontinued or dose-adjusted, resume ALUNBRIG at next lower dose (Table 1) upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above.
Bradycardia with life-threatening consequences, urgent intervention indicated Permanently discontinue ALUNBRIG if no contributing concomitant medication is identified.If contributing concomitant medication is identified and discontinued or dose-adjusted, resume ALUNBRIG at next lower dose (Table 1) upon recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above, with frequent monitoring as clinically indicated.Recurrence: permanently discontinue ALUNBRIG.
Visual Disturbance [see Warnings and Precautions (5.4)]Grade 2 or 3 visual disturbanceWithhold ALUNBRIG until recovery to Grade 1 or baseline, then resume at the next lower dose (Table 1).
Grade 4 visual disturbancePermanently discontinue ALUNBRIG.
Creatine Phosphokinase (CPK) Elevation [see Warnings and Precautions (5.5)]Grade 3 or 4 CPK elevation (greater than 5× ULN) with Grade 2 or higher muscle pain or weaknessWithhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 2.5× ULN) CPK elevation or to baseline, then resume ALUNBRIG at same dose.Recurrence: Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 2.5× ULN) CPK elevation or to baseline, then resume ALUNBRIG at the next lower dose (Table 1).
Lipase/Amylase Elevation [see Warnings and Precautions (5.6)]Grade 3 lipase or amylase elevation (greater than 2× ULN)Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 1.5× ULN) or to baseline, then resume ALUNBRIG at same dose.Recurrence: Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 1.5× ULN) or to baseline, then resume ALUNBRIG at next lower dose (Table 1).
Grade 4 lipase or amylase elevation (greater than 5× ULN)Withhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 1.5× ULN) or to baseline, then resume ALUNBRIG at next lower dose (Table 1).
Hepatotoxicity (Elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)) [see Warnings and Precautions (5.7)]Grade 3 or 4 elevation (greater than 5 × ULN) of either ALT or AST with bilirubin less than or equal to 2 × ULNWithhold ALUNBRIG until recovery to Grade 1 or less (less than or equal to 3× ULN) or to baseline, then resume ALUNBRIG at next lower dose (Table 1).
Grade 2 to 4 elevation (greater than 3 × ULN) of ALT or AST with concurrent total bilirubin elevation greater than 2 × ULN in the absence of cholestasis or hemolysisPermanently discontinue ALUNBRIG.
Hyperglycemia [see Warnings and Precautions (5.8)]Grade 3 (greater than 250 mg/dL or 13.9 mmol/L) or 4If adequate hyperglycemic control cannot be achieved with optimal medical management, withhold ALUNBRIG until adequate hyperglycemic control is achieved and resume at the next lower dose (Table 1) or permanently discontinue ALUNBRIG.
Other Grade 3Withhold ALUNBRIG until recovery to baseline, then resume at same dose.Recurrence: withhold ALUNBRIG until recovery to baseline, then resume at next lower dose or discontinue ALUNBRIG (Table 1).
Grade 4Withhold ALUNBRIG until recovery to baseline and resume at next lower dose (Table 1).Recurrence: Permanently discontinue ALUNBRIG.
"],"spl_patient_package_insert_table":["
PATIENT INFORMATION ALUNBRIG® (uh-lun-brig) (brigatinib) tablets
This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: October 2024
What is the most important information I should know about ALUNBRIG? ALUNBRIG can cause serious side effects, including:Lung problems. ALUNBRIG may cause severe or life-threatening swelling (inflammation) of the lungs any time during treatment, and can lead to death. These lung problems happen especially within the first week of treatment with ALUNBRIG. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms, including:
trouble breathing or shortness of breathchest paincough with or without mucusfever
High blood pressure (hypertension). ALUNBRIG may cause high blood pressure. Your healthcare provider will check your blood pressure before starting and during treatment with ALUNBRIG. Tell your healthcare provider right away if you get headaches, dizziness, blurred vision, chest pain or shortness of breath.Slow heart rate (bradycardia). ALUNBRIG may cause very slow heartbeats that can be severe. Your healthcare provider will check your heart rate during treatment with ALUNBRIG. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint during treatment with ALUNBRIG. Tell your healthcare provider if you take any heart or blood pressure medicines.Vision problems. ALUNBRIG may cause vision problems. Your healthcare provider may stop ALUNBRIG and refer you to an eye specialist if you develop severe vision problems during treatment with ALUNBRIG. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including:
double visionseeing flashes of lightblurry visionlight hurting your eyesnew or increased floaters
Muscle pain, tenderness, and weakness (myalgia). ALUNBRIG may increase the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Your healthcare provider will do blood tests to check your blood levels of CPK during treatment with ALUNBRIG. Tell your healthcare provider right away if you get new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.Inflammation of the pancreas (pancreatitis). ALUNBRIG may increase enzymes in your blood called amylase and lipase, which may be a sign of pancreatitis. Your healthcare provider will do blood tests to check your pancreatic enzyme blood levels during treatment with ALUNBRIG. Tell your healthcare provider right away if you get new or worsening signs and symptoms of pancreatitis, including upper abdominal pain that may spread to the back and get worse with eating, weight loss, or nausea.Liver problems (hepatotoxicity). ALUNBRIG may increase the levels of bilirubin in your blood and enzymes called aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in your blood, which may be a sign of liver problems. Your healthcare provider will do blood tests to check your liver during treatment with ALUNBRIG. Tell your healthcare provider right away if you get new or worsening signs or symptoms, including:
yellowing of your skin or the white part of your eyesdark or brown (tea color) urinenausea or vomitingpain on the right side of your stomach areableed or bruise more easily than normal itchy skindecreased appetitefeeling tired
High blood sugar (hyperglycemia). ALUNBRIG may increase your blood sugar levels. Your healthcare provider will do blood tests to check your blood sugar levels before starting and during treatment with ALUNBRIG. Your healthcare provider may need to start or change your blood sugar medicine to control your blood sugar levels. Tell your healthcare provider right away if you get new or worsening signs and symptoms of hyperglycemia, including:
feeling very thirstyneeding to urinate more than usualfeeling very hungryfeeling sick to your stomachfeeling weak or tiredfeeling confused
See "What are the possible side effects of ALUNBRIG?" for information about side effects.
What is ALUNBRIG? ALUNBRIG is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):that has a certain type of abnormal anaplastic lymphoma kinase (ALK) gene, andthat has spread to other parts of your body.It is not known if ALUNBRIG is safe and effective in children.
Before you take ALUNBRIG, tell your healthcare provider about all of your medical conditions, including if you:have lung or breathing problemshave high blood pressurehave a slow heartbeathave any vision problemshave or have had pancreatitishave liver problemshave diabetes mellitus or glucose intolerancehave kidney problems or are on dialysisare pregnant or plan to become pregnant. ALUNBRIG can harm your unborn baby. Your healthcare provider will determine whether or not you are pregnant before you start treatment with ALUNBRIG. Tell your healthcare provider right away if you become pregnant during treatment with ALUNBRIG or think you may be pregnant.Females who are able to become pregnant should use effective birth control during treatment with ALUNBRIG and for at least 4 months after the final dose of ALUNBRIG. Talk to your healthcare provider about birth control choices that are right for you during treatment with ALUNBRIG.Males who have female partners that are able to become pregnant should use effective birth control during treatment with ALUNBRIG and for at least 3 months after the final dose of ALUNBRIG.are breastfeeding or plan to breastfeed. It is not known if ALUNBRIG passes into your breast milk. Do not breastfeed during treatment with ALUNBRIG and for 1 week after the final dose of ALUNBRIG.Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.
How should I take ALUNBRIG?Take ALUNBRIG exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking ALUNBRIG unless your healthcare provider tells you to.Your healthcare provider will start you on a low dose (90 mg) of ALUNBRIG for the first 7 days of treatment. If you tolerate this dose of ALUNBRIG well, your healthcare provider may increase your dose after the first 7 days of treatment.Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ALUNBRIG if you develop side effects.Take ALUNBRIG 1 time each day.Take ALUNBRIG with or without food.Swallow ALUNBRIG tablets whole. Do not crush or chew tablets.If you miss a dose of ALUNBRIG, do not take the missed dose. Take your next dose at your regular time.If you vomit after taking a dose of ALUNBRIG, do not take an extra dose. Take your next dose at your regular time.
What should I avoid while taking ALUNBRIG?Limit your time in the sun during treatment with ALUNBRIG and for at least 5 days after your final dose. ALUNBRIG may make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. When you are in the sun, wear a hat and protective clothing, and use a broad-spectrum sunscreen and lip balm with a Sun Protection Factor (SPF) of 30 or greater to protect against sunburn.Avoid eating grapefruit or drinking grapefruit juice during treatment with ALUNBRIG. Grapefruit may increase the amount of ALUNBRIG in your blood.
What are the possible side effects of ALUNBRIG? ALUNBRIG may cause serious side effects, including: See "What is the most important information I should know about ALUNBRIG?".The most common side effects of ALUNBRIG include:
diarrheafatiguenausearashcoughmuscle painheadachehigh blood pressurevomitingdifficulty breathing
ALUNBRIG may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility. These are not all of the possible side effects of ALUNBRIG. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ALUNBRIG?Store ALUNBRIG at room temperature between 68°F to 77°F (20°C to 25°C).Keep ALUNBRIG and all medicines out of the reach of children.
General information about the safe and effective use of ALUNBRIG. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ALUNBRIG for a condition for which it was not prescribed. Do not give ALUNBRIG to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about ALUNBRIG that is written for health professionals.
What are the ingredients in ALUNBRIG? Active ingredient: brigatinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide. Distributed by: Takeda Pharmaceuticals America, Inc., Cambridge, MA 02142 ALUNBRIG and are registered trademarks of ARIAD Pharmaceuticals, Inc. ©2024 ARIAD Pharmaceuticals, Inc. All rights reserved. For more information, go to www.alunbrig.com or call 1-844-217-6468. ABG346 R6
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Carton NDC 63020-113-30 ALUNBRIG ® (brigatinib) tablets 30 mg Rx Only 30 Tablets PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Carton","PRINCIPAL DISPLAY PANEL - 90 mg Tablet Bottle Carton NDC 63020-090-30 ALUNBRIG ® (brigatinib) tablets 90 mg Rx Only 30 Tablets PRINCIPAL DISPLAY PANEL - 90 mg Tablet Bottle Carton","PRINCIPAL DISPLAY PANEL - 180 mg Tablet Bottle Carton NDC 63020-180-30 ALUNBRIG ® (brigatinib) tablets 180 mg Rx Only 30 Tablets PRINCIPAL DISPLAY PANEL - 180 mg Tablet Bottle Carton","PRINCIPAL DISPLAY PANEL - Kit Carton NDC 63020-198-30 INITIATION PACK ALUNBRIG ® (brigatinib) tablets Rx Only | Oral Use Usual Dose: One 90 mg tablet orally once daily for the first 7 days; if tolerated, increase to one 180 mg tablet orally once daily. See accompanying full Prescribing Information for complete details. 90 mg 7 Tablets Take 1 tablet on Day 1 - Day 7 180 mg 23 Tablets Take 1 tablet on Day 8 - Day 30 PRINCIPAL DISPLAY PANEL - Kit Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with brigatinib. Treatment with brigatinib resulted in chromosomal damage in an in vivo mammalian erythrocyte micronucleus in the rat, but was not mutagenic in the Ames or in vitro mammalian chromosome aberration tests. Dedicated animal fertility studies were not conducted with brigatinib. Testicular toxicity was observed in repeat-dose animal studies at doses resulting in exposure as low as 0.2 times the exposure in patients at the 180 mg dose. In rats, findings included lower weight of testes, seminal vesicles and prostate gland, and testicular tubular degeneration; these effects were not reversible during the 2 month recovery period. In monkeys, findings included reduced size of testes along with microscopic evidence of hypospermatogenesis; these effects were reversible during the recovery period."]},"tags":[{"label":"Kinase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"ALK tyrosine kinase receptor","category":"target"},{"label":"ALK","category":"gene"},{"label":"ROS1","category":"gene"},{"label":"FLT3","category":"gene"},{"label":"L01ED04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","category":"indication"},{"label":"Non-small cell lung cancer","category":"indication"},{"label":"Takeda Pharms Usa","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"413 reports"},{"date":"","signal":"NON-SMALL CELL LUNG CANCER","source":"FDA FAERS","actionTaken":"385 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"294 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"248 reports"},{"date":"","signal":"METASTASES TO CENTRAL NERVOUS SYSTEM","source":"FDA FAERS","actionTaken":"236 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"227 reports"},{"date":"","signal":"LUNG NEOPLASM MALIGNANT","source":"FDA FAERS","actionTaken":"217 reports"},{"date":"","signal":"BLOOD CREATINE PHOSPHOKINASE INCREASED","source":"FDA FAERS","actionTaken":"215 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"212 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"199 reports"}],"commonSideEffects":[{"effect":"ILD/Pneumonitis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Abdominal pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Rash","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Cough","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dyspnea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Fatigue","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypertension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pyrexia","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Myalgia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Headache","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Pulmonary embolism","drugRate":"2.2%","severity":"serious","_validated":true},{"effect":"Pneumonia","drugRate":"5.1%","severity":"serious","_validated":true},{"effect":"Constipation","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Stomatitis","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Dyspepsia","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Gastroesophageal reflux disease","drugRate":"0.7%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Cerebrovascular accident","drugRate":"0.7%","severity":"serious","_validated":true},{"effect":"Multiple organ dysfunction syndrome","drugRate":"0.7%","severity":"serious","_validated":true},{"effect":"Increased creatine phosphokinase","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Increased lipase","drugRate":"6.6%","severity":"mild","_validated":true},{"effect":"Increased amylase","drugRate":"4.4%","severity":"mild","_validated":true},{"effect":"Increased aspartate aminotransferase","drugRate":"2.2%","severity":"mild","_validated":true}],"specialPopulations":{"Pregnancy":"Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to pregnant woman. There are no clinical data on the use of ALUNBRIG in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by AUC at 180 mg once daily) as well as increased post-implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or greater. Advise pregnant women of the potential risk to fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Geriatric use":"Of the 359 patients enrolled in the ALTA 1L ALUNBRIG arm and in ALTA, 26.7% were 65 and older and 7.5% were 75 and older. No overall differences in safety or effectiveness were observed between patients >=65 years and younger patients.","Paediatric use":"The safety and effectiveness of ALUNBRIG in pediatric patients have not been established.","Renal impairment":"Reduce the dose of ALUNBRIG for patients with severe renal impairment.","Hepatic impairment":"Reduce the dose of ALUNBRIG for patients with severe hepatic impairment."}},"trials":[],"aliases":[],"company":"Takeda","patents":[{"applNo":"N208772","source":"FDA Orange Book","status":"Active","expires":"Apr 10, 2034","useCode":"U-2837","territory":"US","drugProduct":false,"patentNumber":"9611283","drugSubstance":false},{"applNo":"N208772","source":"FDA Orange Book","status":"Active","expires":"May 21, 2029","useCode":"U-2837","territory":"US","drugProduct":false,"patentNumber":"9273077","drugSubstance":false},{"applNo":"N208772","source":"FDA Orange Book","status":"Active","expires":"Nov 10, 2035","useCode":"U-2837","territory":"US","drugProduct":true,"patentNumber":"10385078","drugSubstance":true},{"applNo":"N208772","source":"FDA Orange Book","status":"Active","expires":"Apr 28, 2031","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9012462","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=brigatinib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:48:08.149196+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:48:04.525554+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Brigatinib","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:48:14.917801+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:48:13.543055+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:48:08.216911+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:48:03.281457+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=brigatinib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:48:13.866303+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:02.342240+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:02.342262+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:02.342266+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:48:15.361493+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Epidermal growth factor receptor erbB1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:14.917750+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545311/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:14.578559+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208772","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:02.342269+00:00"}},"allNames":"alunbrig","offLabel":[],"synonyms":["brigatinib","alunbrig","AP26113"],"timeline":[{"date":"2017-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ARIAD to Takeda Pharms Usa"},{"date":"2017-04-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (Ariad)"},{"date":"2018-09-22","type":"positive","source":"DrugCentral","milestone":"EMA approval (Takeda Pharma A/S)"},{"date":"2021-01-22","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Takeda Pharmaceutical Company Limited)"},{"date":"2027-05-22","type":"negative","source":"FDA Orange Book","milestone":"ODE-300 exclusivity expires"},{"date":"2031-04-28","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9012462 expires"},{"date":"2035-11-10","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 10385078 expires"}],"brandName":"Alunbrig","ecosystem":[{"indication":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","otherDrugs":[],"globalPrevalence":2200000},{"indication":"Non-small cell lung cancer","otherDrugs":[{"name":"alectinib","slug":"alectinib","company":"Hoffman-La Roche"},{"name":"ceritinib","slug":"ceritinib","company":"Novartis Pharms Corp"},{"name":"crizotinib","slug":"crizotinib","company":"Pf Prism Cv"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"}],"globalPrevalence":2200000}],"mechanism":{"target":"ALK tyrosine kinase receptor","novelty":"Follow-on","targets":[{"gene":"ALK","source":"DrugCentral","target":"ALK tyrosine kinase receptor","protein":"ALK tyrosine kinase receptor"},{"gene":"ROS1","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase ROS","protein":"Proto-oncogene tyrosine-protein kinase ROS"},{"gene":"FLT3","source":"DrugCentral","target":"Receptor-type tyrosine-protein kinase FLT3","protein":"Receptor-type tyrosine-protein kinase FLT3"},{"gene":"NUAK1","source":"DrugCentral","target":"NUAK family SNF1-like kinase 1","protein":"NUAK family SNF1-like kinase 1"},{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"IGF1R","source":"DrugCentral","target":"Insulin-like growth factor 1 receptor","protein":"Insulin-like growth factor 1 receptor"},{"gene":"INSR","source":"DrugCentral","target":"Insulin receptor","protein":"Insulin receptor"}],"moaClass":"Cytochrome P450 3A Inducers","modality":"Small Molecule","drugClass":"Kinase Inhibitor [EPC]","explanation":"Brigatinib is tyrosine kinase inhibitor with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays. Brigatinib also inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice.At clinically achievable concentrations (<=500 nM), brigatinib inhibited the in vitro viability of cells expressing EML4-ALK and 17 mutant forms associated with resistance to ALK inhibitors including crizotinib, as well as EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. Brigatinib exhibited in vivo antitumor activity","oneSentence":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells.","technicalDetail":"Alunbrig is a potent and selective inhibitor of the ALK tyrosine kinase receptor, with a Ki value of 0.8 nM and a IC50 value of 1.4 nM, making it effective in blocking the phosphorylation of ALK and subsequent downstream signaling pathways."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Brigatinib","title":"Brigatinib","extract":"Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as an inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), as well as several nonreceptor tyrosine kinases such as FAK, FAK2, and FER. It shows activity against ALK-positive non–small cell lung cancer, ALK-positive anaplastic large cell lymphoma (ALCL), and NF2-related schwannomatosis.","wiki_history":"== History ==\n=== Regulatory approval ===\nAriad Pharmaceuticals, Inc. filed an investigational new drug (IND) application to the US FDA on August 29, 2016.\n\nIn 2016, brigatinib was granted orphan drug status by the FDA for treatment of NSCLC.\n\nOn 28 April 2017, it was granted an accelerated approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer (NSCLC); as a 2nd-line therapy for ALK-positive NSCLC.\n\nIn 2020, it was approved as first-line treatment for ALK-positive metastatic NSCLC patients.\n\n=== Commercialization ===\nBrigatinib is manufactured by Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) which is focused on rare cancers. Ariad then was acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) in February 2017 through a tender offer (for $24.00 per share in cash) and subsequent merger of Ariad with Kiku Merger Co., Inc., a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Ariad is an indirect wholly owned subsidiary of Takeda."},"commercial":{"launchDate":"2017","_launchSource":"DrugCentral (FDA 2017-04-28, ARIAD)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5233","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=brigatinib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=brigatinib","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Brigatinib","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:26:54.207659","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:18.234391+00:00","fieldsConflicting":18,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"crizotinib","drugSlug":"crizotinib","fdaApproval":"2011-08-26","patentExpiry":"Oct 8, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ceritinib","drugSlug":"ceritinib","fdaApproval":"2014-04-29","patentExpiry":"Nov 20, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"alectinib","drugSlug":"alectinib","fdaApproval":"2015-12-11","patentExpiry":"May 29, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lorlatinib","drugSlug":"lorlatinib","fdaApproval":"2018-09-21","patentExpiry":"Oct 4, 2038","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"ODE-300","date":"May 22, 2027"},{"code":"ODE-300","date":"May 22, 2027"},{"code":"ODE-300","date":"May 22, 2027"}],"genericName":"brigatinib","indications":{"approved":[{"name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","source":"DrugCentral","snomedId":830151004,"regulator":"FDA","usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Non-small cell lung cancer","source":"DrugCentral","snomedId":254637007,"regulator":"FDA","usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[],"pipeline":[]},"currentOwner":"Takeda Pharms Usa","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"crizotinib","brandName":"crizotinib","genericName":"crizotinib","approvalYear":"2011","relationship":"same-class"},{"drugId":"ceritinib","brandName":"ceritinib","genericName":"ceritinib","approvalYear":"2014","relationship":"same-class"},{"drugId":"alectinib","brandName":"alectinib","genericName":"alectinib","approvalYear":"2015","relationship":"same-class"},{"drugId":"lorlatinib","brandName":"lorlatinib","genericName":"lorlatinib","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03737994","phase":"PHASE2","title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-25","conditions":["Lung Non-Squamous Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":10,"completionDate":"2027-02-10"},{"nctId":"NCT05100069","phase":"","title":"Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Takeda","startDate":"2021-11-01","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":500,"completionDate":"2030-09-30"},{"nctId":"NCT04318938","phase":"PHASE2","title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-03-30","conditions":["NSCLC"],"enrollment":118,"completionDate":"2026-04-30"},{"nctId":"NCT05721950","phase":"","title":"A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2024-01-17","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":154,"completionDate":"2028-12-30"},{"nctId":"NCT04223596","phase":"PHASE2","title":"Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2020-05-04","conditions":["Lung Cancer","NSCLC","NSCLC Stage IIIB","NSCLC Stage IV"],"enrollment":33,"completionDate":"2026-12-30"},{"nctId":"NCT04374305","phase":"PHASE2","title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Scott R. Plotkin, MD, PhD","startDate":"2020-06-20","conditions":["Neurofibromatosis Type 2","Vestibular Schwannoma","Non-vestibular Schwannoma","Meningioma","Ependymoma"],"enrollment":100,"completionDate":"2030-12-01"},{"nctId":"NCT04592523","phase":"","title":"A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea","status":"RECRUITING","sponsor":"Takeda","startDate":"2019-09-05","conditions":["Carcinoma, Non-Small-Cell Lung","Anaplastic Lymphoma Kinase"],"enrollment":257,"completionDate":"2026-08-26"},{"nctId":"NCT04925609","phase":"PHASE1,PHASE2","title":"Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2022-08-18","conditions":["Anaplastic Large Cell Lymphoma, ALK-Positive","Inflammatory Myofibroblastic Tumor","Other Solid Tumor"],"enrollment":65,"completionDate":"2033-12"},{"nctId":"NCT05200481","phase":"PHASE2","title":"Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2022-05-18","conditions":["Non Small Cell Lung Cancer","ALK Gene Mutation"],"enrollment":110,"completionDate":"2028-10"},{"nctId":"NCT03707938","phase":"PHASE1","title":"Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-18","conditions":["Advanced Lung Carcinoma","ALK Gene Rearrangement","Lung Non-Small Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":35,"completionDate":"2026-01-28"},{"nctId":"NCT05384626","phase":"PHASE1,PHASE2","title":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2022-06-09","conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"enrollment":840,"completionDate":"2028-01"},{"nctId":"NCT04227028","phase":"PHASE1","title":"Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-03-09","conditions":["Locally Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":5,"completionDate":"2026-04-21"},{"nctId":"NCT03596866","phase":"PHASE3","title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-04-19","conditions":["ALK+ Advanced NSCLC"],"enrollment":248,"completionDate":"2024-09-18"},{"nctId":"NCT05735327","phase":"","title":"A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-05-22","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":50,"completionDate":"2027-06-01"},{"nctId":"NCT03535740","phase":"PHASE2","title":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","status":"COMPLETED","sponsor":"Ariad Pharmaceuticals","startDate":"2019-01-31","conditions":["ALK-positive Advanced NSCLC"],"enrollment":103,"completionDate":"2024-08-21"},{"nctId":"NCT06620835","phase":"PHASE2","title":"Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib","status":"RECRUITING","sponsor":"Groupe Francais De Pneumo-Cancerologie","startDate":"2025-06-19","conditions":["NSCLC"],"enrollment":45,"completionDate":"2030-10-01"},{"nctId":"NCT05195619","phase":"PHASE1","title":"Personalized DC Vaccines in Non Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2022-03-22","conditions":["Non-small Cell Lung Cancer"],"enrollment":16,"completionDate":"2027-06"},{"nctId":"NCT06522360","phase":"PHASE2","title":"Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-12-11","conditions":["Non-small Cell Lung Cancer"],"enrollment":0,"completionDate":"2025-04-17"},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":["Non-Small Cell Lung Cancer"],"enrollment":5279,"completionDate":"2024-01-23"},{"nctId":"NCT03389399","phase":"","title":"Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-02-22","conditions":["Non-Small Cell Lung Cancer"],"enrollment":18,"completionDate":"2021-10-01"},{"nctId":"NCT06813079","phase":"PHASE2","title":"Using Tumor Models to Determine Treatments","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-02-17","conditions":["Pancreatic Ductal Carcinoma","Advanced Cancer","Epithelial Tumor"],"enrollment":25,"completionDate":"2028-02-17"},{"nctId":"NCT06132867","phase":"PHASE1","title":"A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-12-20","conditions":["Healthy Volunteers"],"enrollment":12,"completionDate":"2024-02-17"},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":["Non Small Cell Lung Cancer","EGFR Gene Mutation","ALK Gene Mutation","ROS1 Gene Mutation","MET Gene Mutation"],"enrollment":6000,"completionDate":"2027-12-24"},{"nctId":"NCT05718297","phase":"PHASE2","title":"Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2024-06-07","conditions":["NSCLC, Stage III","ALK-rearrangement"],"enrollment":0,"completionDate":"2024-09-30"},{"nctId":"NCT05014464","phase":"PHASE2","title":"ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-11-13","conditions":["Non-small Cell Lung Cancer"],"enrollment":90,"completionDate":"2027-08-08"},{"nctId":"NCT06532149","phase":"","title":"ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-08-05","conditions":["NSCLC Stage IV","Sex Disorder","Hypogonadism, Male","Erectile Dysfunction"],"enrollment":80,"completionDate":"2026-09-30"},{"nctId":"NCT06234579","phase":"","title":"Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-12","conditions":["ALK Gene Mutation","NSCLC Stage IV","ALK Sensitizing Mutation"],"enrollment":108,"completionDate":"2026-07-31"},{"nctId":"NCT03546894","phase":"","title":"A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-07-23","conditions":["Anaplastic Lymphoma Kinase-positive","Carcinoma Non-small-cell Lung"],"enrollment":111,"completionDate":"2023-02-13"},{"nctId":"NCT03410108","phase":"PHASE2","title":"Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-01-29","conditions":["ALK-positive Advanced NSCLC"],"enrollment":104,"completionDate":"2021-07-28"},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":["Breast Cancer","Gastrointestinal Cancer","Non Small Cell Lung Cancer","Other Cancer"],"enrollment":400,"completionDate":"2025-06"},{"nctId":"NCT04074993","phase":"PHASE2","title":"Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays","status":"UNKNOWN","sponsor":"JI-YOUN HAN","startDate":"2020-05-15","conditions":["Non Small Cell Lung Cancer"],"enrollment":35,"completionDate":"2025-03-31"},{"nctId":"NCT04887519","phase":"","title":"A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-12-30","conditions":["Carcinoma, Non-Small-Cell Lung","Anaplastic Lymphoma Kinase"],"enrollment":39,"completionDate":"2023-03-31"},{"nctId":"NCT04647110","phase":"","title":"Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-12-14","conditions":["ALK-positive NSCLC"],"enrollment":549,"completionDate":"2021-03-15"},{"nctId":"NCT03420742","phase":"PHASE1","title":"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-06-26","conditions":["Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors"],"enrollment":24,"completionDate":"2021-04-29"},{"nctId":"NCT02706626","phase":"PHASE2","title":"Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors","status":"TERMINATED","sponsor":"Criterium, Inc.","startDate":"2017-03-09","conditions":["Non-Small Cell Lung Cancer"],"enrollment":32,"completionDate":"2021-04-01"},{"nctId":"NCT04634110","phase":"PHASE2","title":"Brigatinib Before Brain Irradiation Trial (B3i Trial)","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2020-11-17","conditions":["Brain Metastases","Lung Cancer"],"enrollment":1,"completionDate":"2022-04-14"},{"nctId":"NCT04005144","phase":"PHASE1","title":"Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2020-02-25","conditions":["ALK Gene Rearrangement","Lung Non-Small Cell Carcinoma","Progressive Disease","ROS1 Gene Rearrangement","Stage IIIB Lung Cancer","Stage IIIC Lung Cancer","Stage IV Lung Cancer","Stage IVA Lung Cancer","Stage IVB Lung Cancer"],"enrollment":3,"completionDate":"2022-10-01"},{"nctId":"NCT05361564","phase":"PHASE2","title":"A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2022-06","conditions":["Non-small Cell Lung Cancer"],"enrollment":12,"completionDate":"2024-06"},{"nctId":"NCT03868423","phase":"PHASE2","title":"Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers","status":"WITHDRAWN","sponsor":"Sameek Roychowdhury","startDate":"2019-03-20","conditions":["Advanced Malignant Neoplasm","ALK Fusion Protein Expression","ALK Gene Amplification","ALK Gene Mutation","Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Neoplasm in the Central Nervous System","Metastatic Malignant Solid Neoplasm","ROS1 Fusion Positive","ROS1 Gene Amplification","ROS1 Gene Mutation"],"enrollment":0,"completionDate":"2021-12-30"},{"nctId":"NCT04718012","phase":"","title":"Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-03-17","conditions":["Lung Cancer ROS Translocated"],"enrollment":22,"completionDate":"2021-10-17"},{"nctId":"NCT02737501","phase":"PHASE3","title":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","status":"COMPLETED","sponsor":"Ariad Pharmaceuticals","isPivotal":true,"startDate":"2016-05-26","conditions":["Non-small Cell Lung Cancer","Lung Cancer","Advanced Malignancies","Carcinoma"],"enrollment":275,"completionDate":"2021-01-29"},{"nctId":"NCT01449461","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)","status":"COMPLETED","sponsor":"Ariad Pharmaceuticals","startDate":"2011-09-20","conditions":["Lymphoma, Large-Cell, Anaplastic","Carcinoma, Non-Small-Cell Lung"],"enrollment":137,"completionDate":"2020-02-18"},{"nctId":"NCT02094573","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","status":"COMPLETED","sponsor":"Ariad Pharmaceuticals","isPivotal":true,"startDate":"2014-06-04","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":222,"completionDate":"2020-02-27"},{"nctId":"NCT03719898","phase":"PHASE2","title":"Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fox Chase Cancer Center","startDate":"2018-12-06","conditions":["Anaplastic Large Cell Lymphoma, ALK-Positive"],"enrollment":0,"completionDate":"2020-06-16"},{"nctId":"NCT04260009","phase":"PHASE1,PHASE2","title":"Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2020-09-01","conditions":["Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma","Inflammatory Myofibroblastic Tumors","Solid Tumors"],"enrollment":0,"completionDate":"2025-09-01"},{"nctId":"NCT02784158","phase":"","title":"An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Ariad Pharmaceuticals","startDate":"","conditions":["Non-small Cell Lung Cancer","Lung Cancer","Advanced Malignancies","Carcinoma"],"enrollment":0,"completionDate":""}],"_emaApprovals":[{"date":"2018-09-22","status":"Authorised","company":"TAKEDA PHARMA A/S"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02737501","NCT02094573"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Alunbrig"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"256904","NDDF":"017195","UNII":"HYW8DB273J","VANDF":"4036651","INN_ID":"10085","RXNORM":"1921217","UMLSCUI":"C4287815","chemblId":"CHEMBL3545311","ChEMBL_ID":"CHEMBL3545311","KEGG_DRUG":"D10866","DRUGBANK_ID":"DB12267","PDB_CHEM_ID":" 6GY","PUBCHEM_CID":"68165256","SNOMEDCT_US":"736634002","IUPHAR_LIGAND_ID":"7741","MESH_SUPPLEMENTAL_RECORD_UI":"C000598580"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2017-","companyName":"Ariad","relationship":"Original Developer"},{"period":"present","companyName":"Takeda","relationship":"Current Owner"},{"period":"2018","companyName":"Takeda Pharma A/S","relationship":"EMA Licensee"},{"period":"2021","companyName":"Takeda Pharmaceutical Company Limited","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"25 hours"},"publicationCount":543,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01ED04","allCodes":["L01ED04"]},"biosimilarFilings":[],"originalDeveloper":"Ariad","recentPublications":[{"date":"2026 Mar 22","pmid":"41898726","title":"Emerging Molecular Insights and Therapeutic Directions in Neurofibromatosis Type 1 and NF2-Related Schwannomatosis.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 21","pmid":"41893038","title":"Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review.","journal":"Journal of personalized medicine"},{"date":"2026 Feb 26","pmid":"41827693","title":"GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.","journal":"Cancers"},{"date":"2026 Mar 11","pmid":"41810993","title":"Brigatinib-induced psoriasiform dermatitis successfully treated with deucravacitinib.","journal":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG"},{"date":"2026 Feb 19","pmid":"41756440","title":"N-Cadherin Dynamically Regulates Schwannoma Migration and Represents a Novel Therapeutic Target in NF2-Related Schwannomatosis.","journal":"Research square"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Takeda Pharms Usa","companyId":"takeda","modality":"Small Molecule","firstApprovalDate":"2017","aiSummary":"","enrichmentLevel":4,"visitCount":3,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-10-02T00:00:00.000Z","mah":"TAKEDA PHARMS USA","brand_name_local":null,"application_number":"NDA208772"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":14,"withResults":6},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:18.234391+00:00","fieldsConflicting":18,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}